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SUMMARY 
Background: Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common 
childhood psychiatric disorders, estimated to affect about 5% of school-aged children worldwide. 
According to the Diagnostic and Statistical Manual of Mental Disorders-4th edition-Text Revision 
(DSM-IV-TR), ADHD is defined by a persistent and age-inappropriate pattern of inattention, 
hyperactivity-impulsivity or both. The exact etiopathogenesis underlying ADHD is not completely 
understood. It is likely that ADHD is an heterogeneous syndromic entity with a multifactorial 
etiopathogenesis, including genetic and environmental factors. Several lines of evidence, reviewed 
in detail in the first part of the thesis, suggest that iron deficiency (ID) might be involved in the 
etiopathogenesis of ADHD. First, iron is a co-factor of enzymes necessary for the synthesis and 
catabolism of the aminergic neurotransmitters (dopamine, serotonin, and noradrenaline), which 
have been shown to be involved in the pathophysiology of ADHD. Second, iron deficiency is 
associated with a decrease in dopamine D2 receptors, as well as of dopamine transporter in basal 
ganglia (in particular in the striatum), which have been implicated in ADHD pathogenesis. Third, 
there is a large body of research showing that ID with or without anemia in childhood is associated 
with cognitive and behavioral impairments, including poor attention and hyperactivity. Fourth, ID 
in basal ganglia is also increasingly recognized as a central factor in the pathophysiology of 
Restless Legs Syndrome, which may be co-morbid with ADHD, thus suggesting possible common 
pathophysiologic pathways in which iron deficiency may play a role. Finally, overweight, which is 
more common in children with ADHD than controls, has been associated with iron deficiency.  
Rationale: To date, available studies on ID in ADHD are based on the measure of serum ferritin, a 
peripheral marker of ID. However, how well peripheral iron indices correlate with central (i.e. 
brain) iron content is still unclear. Since it is central iron that may impact on brain function, there is 
a need to assess brain iron levels in children with ADHD. No published study has assessed brain 
iron levels in children with ADHD by means of Magnetic Resonance Imaging (MRI).  
Aims: The aims of the study, presented in the second part of the thesis, are the following: Primary: 
To compare brain iron levels, estimated by means of MRI, in a sample of children with ADHD, in a 
group of children with other psychiatric disorders (different from ADHD), and in a group of healthy 
controls. Iron levels were estimated in four regions which have been shown to contain iron: 
thalamus, putamen, pallidum, and caudate. Secondary: To assess the relationship between serum 
ferritin levels and estimated brain iron levels in the three study groups. 
Methods: Subjects: Patients (6-14 years) with ADHD, as well as those with other psychiatric 
disorders, were recruited from the Child and Adolescent Psychopathology Unit of the Hospital 
Robert Debré in Paris (2006-2008). Healthy controls were recruited from relatives of hospital 
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employees. Non-inclusion criteria were the presence of one or more neurologic disorders, a 
previous or ongoing iron supplementation, anemia, and the current use of any drug that could 
significantly affect cognitive function. Procedures: Psychiatric evaluation: The diagnosis of ADHD, 
as well as of other psychiatric disorders, was made according to DSM-IV-TR criteria and was 
confirmed by the semi-structured interview Kiddie-SADS-PL. The Kiddie-SADS-PL confirmed the 
absence of any relevant psychiatric disorder in the control group. Assessment of peripheral iron 
status: A complete blood count and measurement of serum ferritin levels, as well as of serum iron 
and hemoglobin (Tinaquant and Ferrozine method) were obtained. MRI measurements: Estimation 
of brain iron was obtained on the basis of T2*. The inverse of T2* (R2*) are directly correlated 
with iron stores. MRI examinations were performed on a 1.5 T Philips Unit. Statistical analysis: 
T2* were compared in the three study groups using one-way ANOVA analysis with Bonferroni 
multiple comparison procedure. The correlation between serum ferritin levels and estimated brain 
iron levels in the four regions was assessed by means of the Spearman correlation. All statistical 
analyses were performed using SPSS v. 15.0 (SPSS, Inc., Chicago, IL, USA). 
Results: Data from eighteen children with ADHD, nine patients with other psychopathologies 
(Anxiety Disorders, Mood Disorders, Obsessive Compulsive Disorder, and Early Schizophrenia), 
and nine healthy controls were used for the statistical analysis. According to the power analysis, this 
sample size allowed for a detection of a difference of 2 points in T2* with a power of about 85%. It 
was found that T2* were significantly higher (meaning that iron levels were significantly lower) in 
thalamus, both in right (p= 0.015) and in left thalamus (p= 0.010) in children with ADHD compared 
to healthy controls. No other significant differences were found for the other regions of interest. 
Children with ADHD had serum ferritin levels significantly lower than children with other 
psychiatric disorders (p =0.006) and healthy controls (p=0.001). Serum ferritin levels were 
inversely correlated with T2*, but the correlations were not significant in any regions of interest (p> 
0.005). 
Discussion: This is the first study to assess brain iron levels in children with ADHD. MRI data 
suggest that low iron levels in thalamus might impair its functioning in children with ADHD. 
Although the thalamus has been scarcely investigated in ADHD, it is presumed to be a very critical 
brain region subserving normal attention processes. Iron deficiency might negatively impact 
thalamic functioning also in other psychiatric disorders, but further studies are needed to assess to 
what extent iron deficiency is specific of ADHD or can be found in other psychiatric disorders. 
Serum ferritin levels inversely increased with T2*, but the correlation was not significant. Although 
low peripheral iron levels may negatively impact on brain iron, our results suggest that serum 
ferritin levels might be only a proxy for brain iron but can not estimate it accurately. 
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Conclusions and future perspectives: This study provides a significant contribution to our 
understanding of the pathophysiology of ADHD, suggesting that brain iron deficiency might 
contribute to the pathophysiology of ADHD (and perhaps of other childhood psychiatric disorders) 
via its impact on thalamic functioning, which is part of neuronal circuits serving attention and 
alertness. Further studies, with novel MRI approaches to better estimate brain iron, are needed to 
confirm our results. This body of research might contribute to advance our knowledge on the 
etiopathogenesis and pathophysiologic pathways underlying the cluster of ADHD symptoms. The 
approach which underlies the rationale of these studies is an innovative one in the field of ADHD, 
and, in general, in child psychiatry, moving from the description of syndromes to pathophysiology-
based disorders. This approach would also lay the groundwork for interesting treatment 
applications. In fact, it has been reported that the effect of ADHD drugs acting on the dopaminergic 
and noradrenergic systems is reduced in the presence of iron deficiency. Therefore, if further 
research confirms low brain iron levels in ADHD, it would provide a strong rationale for trials 
assessing the effects of ADHD medications plus iron supplementation for ADHD. This might 
contribute to improve our current clinical practice, thus allowing for a better quality of life of 
children with ADHD and their families.  
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1.1.1 Definition and clinical features 
 
Problems of inattention, hyperactivity, and/or impulsivity represent one of the most common 
reasons for referral to child neuropsychiatric services. According to the Diagnostic and Statistical 
Manual of Mental Disorders-4th edition (DSM-IV)1 and its updated version (Text Revision, TR)2, 
Attention-Deficit/Hyperactivity Disorder (ADHD) is defined by a persistent and age-inappropriate 
pattern of inattention, hyperactivity-impulsivity or both. Onset before the age of seven and impaired 
functioning in two or more settings are currently required for the diagnosis. The DSM-IV1 and IV-
TR2 define four types of ADHD: “predominantly inattentive”, “predominantly hyperactive-
impulsive”, “combined”, and “not otherwise specified”.  
The International Classification of Diseases–10th Edition (ICD-10)3 defines a more narrow 
and severe syndrome, i.e. the Hyperkinetic Disorder (HKD), including a more rigorous criterion for 
pervasiveness than does DSM-IV-TR, requiring all the three types of symptoms (inattention, 
hyperactivity, and impulsivity) and discouraging the use of multiple diagnoses (but allowing for a 
diagnosis of hyperkinetic conduct disorder). Thus, HKD can be approximately assimilated to the 
combined type of ADHD. 
DSM-IV-TR criteria for the diagnosis of ADHD and ADHD types and ICD-10 criteria for 
the diagnosis of HKD are reported in Table 1 and Table 2, respectively.  
 
 
 
 
 
 
 
Tab. 1. DSM-IV-TR criteria for the diagnosis of Attention-Deficit/Hyperactivity Disorder 
(ADHD). 
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____________________________________________________________________________________________ 
 
A. Either (1) or (2) 
  
(1). 6 (or more) of the following symptoms of inattention have persisted for at least 6 months to a degree that 
is maladaptive and inconsistent with developmental level:  
 
Inattention  
(a) often fails to give close attention to details or makes careless mistakes in schoolwork, work, or other 
activities  
(b) often has difficulty sustaining attention in tasks or play activities  
(c) often does not seem to listen when spoken to directly  
(d) often does not follow through on instructions and fails to finish  
schoolwork, chores, or duties in the workplace (not due to oppositional behaviour or failure to understand 
instructions)  
(e) often has difficulty organising tasks and activities  
(f) often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (such as 
schoolwork or homework).  
(g) often loses things necessary for tasks or activities (e.g. toys, school assignments, pencils, books, or tools)  
(h) is often easily distracted by extraneous stimuli  
(i) is often forgetful in daily activities  
(2) 6 (or more) of the following symptoms of hyperactivity-impulsivity have persisted for at least 6 months 
to a degree that is maladaptive and inconsistent with developmental level  
 
Hyperactivity  
(a) often fidgets with hands or feet or squirms in seat  
(b) often leaves seat in classroom or in other situations in which remaining seated is expected  
(c) often runs about or climbs excessively in situations in which it is inappropriate (in adolescents or adults, 
may be limited to subjective feelings of restlessness)  
(d) often has difficulty playing or engaging in leisure activities quietly  
(e) is often "on the go" or often acts as if "driven by a motor"  
(f) often talks excessively 
  
Impulsivity  
(g) often blurts out answers before questions have been completed  
(h) often has difficulty awaiting turn  
(i) often interrupts or intrudes on others (e.g. butts into conversations or games)  
B. Some hyperactive-impulsive or inattentive symptoms that caused impairment were present before age 7 
years.  
C. Some impairment from the symptoms is present in two or more settings (e.g. at school [or work] and at 
home).  
D. There must be clear evidence of clinically significant impairment in social, academic, or occupational 
functioning.  
E. The symptoms do not occur exclusively during the course of a Pervasive Developmental Disorder, 
Schizophrenia, or other Psychotic Disorder and are not better accounted for by another mental disorder (e.g. 
Mood Disorder, Anxiety Disorder, Dissociative Disorder, or a Personality Disorder) 
  
314.01 ADHD, Combined Type - if both A1 and A2 for at least 6 months  
314.00 ADHD, Predominantly Inattentive Type  
314.01 ADHD, Predominantly Hyperactive-Impulsive Type 
___________________________________________________________________________________________________________ 
 
 
 
Tab. 2. ICD-10 criteria for the diagnosis of Hyperkinetic Disorders 
__________________________________________________________________________________________________________  
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G1 At least six of the following symptoms of attention have persisted for at least six months, to a degree that is 
maladaptive and inconsistent with the developmental level of the child:  
· (1) often fails to give close attention to details, or makes careless errors in school work, work or other 
activities;  
· (2) often fails to sustain attention in tasks or play activities;  
· (3) often appears not to listen to what is being said to him or her;  
· (4) often fails to follow through on instructions or to finish school work, chores, or duties in the workplace (not 
because of oppositional behaviour or failure to understand instructions);  
· (5) is often impaired in organising tasks and activities;  
· (6) often avoids or strongly dislikes tasks, such as homework, that require sustained mental effort;  
· (7) often loses things necessary for certain tasks and activities, such as school assignments, pencils, books, toys 
or tools;  
· (8) is often easily distracted by external stimuli;  
· (9) is often forgetful in the course of daily activities.  
G2 At least three of the following symptoms of hyperactivity have persisted for at least six months, to a degree that is 
maladaptive and inconsistent with the developmental level of the child:  
· (1) often fidgets with hands or feet or squirms on seat;  
· (2) leaves seat in classroom or in other situations in which remaining seated is expected;  
· (3) often runs about or climbs excessively in situations in which it is inappropriate (in adolescents or adults, 
only feelings of restlessness may be present);  
· (4) is often unduly noisy in playing or has difficulty in engaging quietly in leisure activities;  
· (5) exhibits a persistent pattern of excessive motor activity that is not substantially modified by social context 
or demands.  
G3 At least one of the following symptoms of impulsivity has persisted for at least six months, to a degree that is 
maladaptive and inconsistent with the developmental level of the child:  
· (1) often blurts out answers before questions have been completed;  
· (2) often fails to wait in lines or await turns in games or group situations;  
· (3) often interrupts or intrudes on others (e.g. butts into others’ conversations or games);  
· (4) often talks excessively without appropriate response to social constraints.  
G4 Onset of the disorder is no later than the age of seven years.  
G5 Pervasiveness  
The criteria should be met for more than a single situation, e.g. the combination of inattention and hyperactivity should 
be present both at home and at school, or at both school and another setting where children are observed, such as a 
clinic. (Evidence for cross-situationality will ordinarily require information from more than one source; parental reports 
about classroom behaviour, for instance, are unlikely to be sufficient.)  
G6 The symptoms in G1 and G3 cause clinically significant distress or impairment in social, academic, or occupational 
functioning.  
G7 The disorder does not meet the criteria for pervasive developmental disorders (F84.-), manic episode (F30.-), 
depressive episode (F32.-), or anxiety disorders (F41.-).  
__________________________________________________________________________________________________________ 
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Deficits in executive functions (defined as set of cognitive skills that are necessary to plan, 
monitor and execute a sequence of goal-directed complex actions and including inhibition, working 
memory, planning, and sustained attention) are common, although far from universal, in ADHD4. 
Evidence from several clinical as well as epidemiological studies has well established that 
ADHD is frequently co-morbid with other psychiatric and neuro-developmental disorders. It has 
been reported that 54% to 84% of children and adolescents with ADHD may meet criteria for 
oppositional defiant disorder (ODD); a significant portion of these patients will develop conduct 
disorder (CD) 5;6. Fifteen percent to 19% of patients with ADHD will start to smoke7 or develop 
other substance abuse disorders8. About 25%-35% of patients with ADHD present with learning or 
language problem9. Anxiety disorders occur in up to one third of patients with ADHD9. The 
prevalence of mood disorders in patients with ADHD is more controversial, with an estimated 
prevalence between 0% to 33% of patients with ADHD meeting criteria for a depressive disorder 9. 
The prevalence of mania among patients with ADHD remains a contentious issue9. It has also been 
reported a relationship between ADHD and Tourette’s Syndrome (TS): about 10-30% of ADHD 
patients meet criteria for TS10. Mental retardation and borderline intellectual functioning are 
commonly mislabelled ADHD, although they often co-occur with ADHD11. However, the 
relationship between ADHD and mental retardation/borderline intellectual functioning needs further 
investigation12. Finally, although DSM-IV-TR criteria prohibits the co-diagnosis of ADHD and an 
autism spectrum disorder (ASD), recent studies indicate that co-occurrence of clinically significant 
ADHD and autistic symptoms is common, and that some genes may influence both disorders, 
suggesting that an eventual diagnosis of ADHD in patients with ASD may prompt the appropriate 
management of inattention, hyperactivity and impulsivity in patients with ASD13. 
Because of inattention, hyperactivity/impulsivity, and eventual co-morbidities, children with 
ADHD suffer from various combinations of impairments in functioning at school, at home, and 
with peers. School-based problems include lower than expected or erratic grades, achievement test 
scores, and intelligence test scores, with possible grade retention. Behavioral difficulties related to 
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ADHD or to the combination with co-morbid conditions often lead to constant friction among the 
schoolmates, peers, the teacher, and the parents. Peers often quickly reject ADHD children, due to 
their impulsivity and noncompliance with rules11. 
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1.1.2 Epidemiology 
Considering that ADHD is a clinical diagnosis, the criteria adopted and validity of measures 
used play a major role in the results that are generated by epidemiological studies.  
In the most recent and comprehensive meta-analysis14 including 102 studies comprising 171, 
756 subjects from several world regions, the aggregated prevalence of ADHD based on all studies 
was 5.29% (95% CI, 5.01–5.56). The pooled prevalence for children and adolescents were 
respectively 6.48% (4.62–8.35) and 2.74% (2.04–3.45). However, the estimate was associated with 
significant variability, with prevalences ranging from very low estimates of 0.2% to much higher 
estimates, up 27%. In the multivariate meta-regression model, diagnostic criteria, source of 
information, requirement of impairment for diagnosis, and geographic origin of the studies were 
significantly associated with ADHD prevalence rates. As expected, studies without a definition of 
impairment had significantly higher ADHD prevalence rates than those with a definition of 
impairment. Studies based on DSM-III-R or ICD-10 criteria, respectively, had significantly lower 
ADHD prevalence rates than those using DSM-IV criteria. Studies that relied on information 
provided by parents, teachers, and “or rule” (a symptom is considered present if it is endorsed by 
parents or teachers), respectively, were associated with significantly higher ADHD prevalence rates 
than those relying on a “best-estimate procedure” (merging of parental and teacher reports), 
whereas those relying on information provided using the “and rule” criterion (a symptom is 
considered present only if it is endorsed by both parents and teachers) were associated with 
significantly lower ADHD prevalence estimates. Geographic location was associated with 
significant variability only between estimates from North America and both Africa and the Middle 
East. No significant differences were found between Europe and North America. Therefore, 
geographic location plays a limited role in the reasons for the large variability of ADHD prevalence 
estimates worldwide. Instead, this variability seems to be explained primarily by the methodological 
characteristics of studies 
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Until cross-national studies are performed using parallel diagnostic interview methods, 
identical or comparable sampling frames, and similarly defined populations, determining whether 
meaningful differences exist among countries will not be possible. 
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1.1.3 Etiology  
The etiology of ADHD includes genetic and environmental factors 
Genetic factors 
According to twin and adoption studies, genes play a relevant role in initiating ADHD. It has 
been estimated that the heritability of ADHD is about 0.76, meaning that genetic factors account for 
about 80% of the etiology of ADHD4. 
Genome-wide scans that have been conducted thus far show divergent findings. Moreover, 
so far, candidate gene studies have shown that, for ADHD, genes with moderately large effects are 
unlikely to exist. The variability in findings and lack of replication is presumed to be due, at least in 
part, to diagnostic heterogeneity15. 
However, the following genes have been reported to have a small but significant effect: the 
dopamine D4 receptor gene (DRD4), the dopamine D5 receptor gene (DRD5), the dopamine 
transporter gene (SLC6A3), the synaptosomal-associated protein of 25kD gene (SNAP25), and the 
serotonin 1B receptor gene (HTR1B). This is consistent with the idea that the genetic vulnerability 
to ADHD is mediated by many genes of small effects16. 
By contrast with these positive findings, studies of other genes possibly involved in the 
neurobiology of ADHD on theoretical bases, have produced equivocal or negative results. They 
include: the dopamine D2 and D3 receptor gene (DRD2 and DRD3), the dopamine beta-
hydroxylase gene (DBH), the catechol-O-methyltransferase gene (COMT), the monoamine oxidase-
A (MAO-A), the tryptophan hydroxylase-2 gene (TPH-2), the norepinephrine transporter gene 
(SLC6A2), the serotonin transporter gene (SLC6A4), the nicotinic acetylcholine receptors 
(CHRNA4), the glutamate receptor gene (GRIN2A), the 2A, 2C, and 1C norepinephrine 
receptors16, and the brain-derived neurotrophic factor gene (BDNF). 
Environmental factors 
Environmental factors may be classified as pre-natal, peri-natal, and post-natal in origin. 
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Proposed pregnancy- and birth-related risk factors include maternal smoking, exanthema, maternal 
anemia, breech delivery, prematurity, low birth weight, hypoxic-ischemic encephalopathy, small 
head circumference, cocaine and alcohol exposure, lead exposure, and iodine and thyroid 
deficiency. Childhood illnesses associated with occurrence of ADHD include viral infections, 
meningitis, encephalitis, otitis media, anemia, cardiac disease, thyroid disease, epilepsy, and 
autoimmune and metabolic disorders. Other causative factors might include head injury involving 
the frontal lobes, toxins and drugs, and nutritional disorders, the involvement of many being 
controversial (e.g., food additives, food allergies, sucrose, gluten sensitivity, and fatty acids)17.  
Among all these proposed risk factors, maternal smoking has attracted the greatest attention 
in the recent literature. A systematic search of the literature found 24 studies on maternal tobacco 
smoking published between 1973 and 2002, all of which indicated an increased risk of ADHD in 
the offspring18.  
In contrast to the risk of ADHD with prenatal nicotine exposure, the results of studies that 
have linked alcohol with ADHD are less uniform, and the findings reported from 9 alcohol studies 
have been contradictory17. 
Although the results of the available studies have been variable, lead, and particularly 
prenatal exposure to lead, seems to be a risk factor for ADHD17 
The role of prematurity and peri-natal hypoxic-ischemic encephalopathy have been 
extensively investigated. About one third of premature infants with birth weights of <1500 g have 
been reported to have ADHD4;18. 
Viral infections during pregnancy, at birth, and in early childhood have been linked to an 
increased risk of developing ADHD. Measles, varicella, rubella, HIV, enterovirus 71, and varicella 
zoster encephalitis have been reported to have a significant association with ADHD. Although 
typical ADHD seems to have a weak association with otitis media, some researchers consider a 
history of significant middle-ear disease in early childhood to be a risk factor for hyperactivity and 
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especially speech and language disorders in children who present with learning problems in 
school17.  
In a high proportion of post natal factors, a genetic factor is a likely basic cause, and the 
environmental factor is likely to act as a trigger. 
Studies have provided variable results on zinc deficiency, omega-3 fatty acids, and iodine 
deficiency and therefore their significance is controversial17  
It has also been shown that chronic conflict, reduced family cohesion, and exposure to 
parental psychopathology (especially maternal psychopathology) were more common in ADHD 
families compared with control families. In these studies, the differences between children with or 
without ADHD were not accounted for by social class or by parental history of major 
psychopathology4. 
Gene-environment interaction is increasingly recognized as an important mechanism in the 
etiology and development of ADHD, with some genes (e.g., DAT1) affecting the individual 
sensitivity to environmental etiologic factors4;16;17. 
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1.1.4 Pathophysiology 
The pathophysiology of ADHD is not completely understood, although imbalances in 
dopaminergic and noradrenergic systems have been implicated in the core symptoms that 
characterize this disorder19. 
The overt behavioral signs of ADHD (i.e., excessive inattention, hyperactivity, and 
impulsivity) are thought to result from underlying deficits in response inhibition, delay aversion, 
and executive functioning20. In turn, these neuropsychological deficits are presumed to be linked to 
structural and functional brain abnormalities in frontal-striatal-cerebellar circuits20.  
So far, research has shown that the complex pathophysiology of ADHD, like that of other 
psychiatric disorders, is reflected in microscopic and quantitative, rather than macroscopic and 
qualitative, differences in brain development. 
Imaging studies carried out in the last 20 years have helped elucidating the brain structures 
potentially involved in the pathophysiology of ADHD.  
According to the largest study performed to date compared regional brain volumes of 152 
children and adolescents who had ADHD and 139 controls children with ADHD, overall cerebral 
volumes were 3.2% smaller in children with ADHD than controls, affecting all four major lobes 
(frontal, parietal, temporal, and occipital)21. Further studies have confirmed these data and 
suggested that this effect may not be accounted for by age, height, weight, or IQ20. 
Beyond differences in brain volume, there is more conflicting evidence than certainties. 
Although converging findings from studies on the neuropharmacology, genetics, neuropsychology, 
and neuroimaging of ADHD attribute a central role to fronto-striatal pathway disruption in ADHD, 
current theories suggest that the disorder may result from a disruption in a more distributed 
circuitry, including the frontal brain regions, as well as the basal ganglia, the cerebellar 
hemispheres, and the cerebellar vermis. 
According to a recent meta-analysis of structural MRI studies by Valera et al.22, the pooled 
data from available imaging studies suggest that children with ADHD present with a significant 
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global brain reduction compared to control subjects, with the largest differences observed in 
cerebellar vermis, corpus callosum, total and right cerebral volume, and right caudate.  
Frontal cortex 
Numerous structural neuroimaging studies have reported significantly smaller volumes of 
the frontal cortex in children who have ADHD compared with healthy controls22;23. This volume 
decrease appears to be particularly significant in the right prefrontal cortex, reducing the typical 
right greater than left asymmetry of the prefrontal cortex in children who have ADHD. 
Moreover, functional imaging studies have shown that the expected increase in prefrontal 
metabolism during response inhibition tasks is reduced markedly in ADHD subjects23. A recent  
meta-analysis24 of 16 published functional neuroimaging studies of ADHD revealed that significant 
patterns of frontal hypoactivity are detected across studies in patients who have ADHD, affecting 
anterior cingulate, dorsolateral prefrontal, and inferior prefrontal cortices. More recently, Shaw and 
colleagues25 examined the relationships among cortical thickness measures, baseline diagnosis, and 
clinical outcome in the NIMH cohort of children and adolescents who had ADHD. Results 
confirmed previous findings of cortical abnormalities, prominently in medial and superior prefrontal 
and precentral regions, which are important for attentional control and motor output. The same 
group also reported a longitudinal comparison of cortical thickness between patients with ADHD 
and healthy controls. They showed that rather than a deviation from typical development, ADHD 
exhibited a marked delay in reaching peak thickness in most cortical regions. 
Basal ganglia 
As the caudate nuclei and associated subcortical circuits receive inputs from cortical regions 
implicated in executive functioning and attentional processes, research has also focused on the role 
of the basal ganglia on the pathophysiology of ADHD. 
One of the earliest studies reported decreased metabolism in the striatal region, particularly 
the right caudate26. Later studies have shown size reductions of the right globus pallidus and smaller 
volumes of left and right caudate27. Indices of asymmetry are intrinsically less reliable: right greater 
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than left and left greater than right asymmetries and symmetric caudate volumes have all been 
reported to be associated with ADHD20. A study by Castellanos and colleagues21, however, found 
that such volumetric differences may be transient and possibly related to developmental changes in 
symptoms of ADHD with increasing age.  
Cerebellum 
A significantly smaller posterior inferior lobe (lobules VIII-X) of the vermis consistently has 
been replicated in ADHD20. In a longitudinal study21, the global nonprogressive reduction in total 
volume was shown to be more specific to the superior cerebellar vermis, a region that exhibited a 
volumetric developmental trajectory associated with better or worse clinical outcomes28. 
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1.1.5 Assessment 
According to the practice parameters of the American Academy of Child and Adolescent 
Psychiatry9, screening for ADHD should be part of every patient’s mental health assessment by 
specifically asking questions regarding the major symptom domains of ADHD (inattention, 
impulsivity, and hyperactivity) and asking whether such symptoms cause impairment. If a parent 
reports that the patient suffers from any symptoms of ADHD, then a full evaluation for ADHD is 
indicated9. 
The history/intake interview focusing on the chief complaints about inattention, impulsivity, 
distractibility, and hyperactivity at school and at home, and specifically addressing the DSM-IV 
criteria for ADHD, is the cornerstone of the diagnostic assessment for ADHD9. The clinician should 
perform a detailed interview with the parent about each of the 18 ADHD symptoms listed in DSM-
IV. For each symptom, the clinician should determine whether it is present as well as its duration, 
severity, and frequency. Age at onset of the symptoms should be assessed. The patient must have 
the required number of symptoms, a chronic course, and onset of symptoms during childhood. 
Presence of impairment should be distinguished from presence of symptoms. For instance, a 
patient’s ADHD symptoms may be observable only at school but not at home. Nonetheless, if the 
patient must spend an inordinate amount of time completing schoolwork in the evening that was not 
done in class, then impairment is present in two settings. DSM-IV requires impairment in at least 
two settings (home, school, or job) to meet criteria for the disorder, but clinical consensus agrees 
that severe impairment in one setting warrants treatment9. After reviewing the ADHD symptoms, 
the clinician should interview the parent regarding other common psychiatric disorders of 
childhood. Formal structured and semi-structured interviews like the Schedule for Affective 
Disorders and Schizophrenia for School-Age Children29, the National Institute of Mental Health 
(NIMH) Diagnostic Interview Schedule for Children30, the DSM-based Diagnostic Interview For 
Children and Adolescents (DICA)31, and the Child and Adolescent Psychiatric Assessment32 are 
available. Questionnaires, such as the Conners Parent33 and Teacher34 Rating Scales–Revised (CRS-
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R) are an important and efficient part of the diagnostic assessment but cannot be used in isolation to 
make a diagnosis of ADHD.  
The most commonly used questionnaires to assess ADHD symptoms are reported in Tab. 3. 
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Tab. 3. Questionnaires for the assessment of ADHD symptoms (From: Pliszka et al., 
JAACAP, 20079). 
. 
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Teachers, parents, and older children can/should all report on symptoms to assess for 
agreement/validity of diagnosis, to document that the ADHD symptoms occur in multiple settings, 
and to take advantage of the special information that each can provide. Multiple informants 
(parents, teachers, youths, and health care professionals) do not necessarily agree on diagnosis. If 
the teacher cannot provide such a rating scale or the parent declines permission to contact the 
school, then materials from school, such as work samples or report cards, should be reviewed or 
inquired about. Care must be taken to determine the best interpretation of the data if disagreements 
occur. 
A thorough medical history is part of the initial evaluation. For example, as reported in the 
previous section, prematurity and frequent episodes of otitis with hearing loss may be risk factors of 
ADHD. A complete family history for ADHD and its common co-morbidities should be taken. 
ADHD is a highly heritable disorder, and, although a positive family history does not confirm the 
diagnosis, it can be supportive. Moreover, because patients with ADHD perform better in structured 
settings, any factors in the family that create an inconsistent, disorganized environment may further 
impair the patient’s functioning. 
After interviewing the parents, the clinician should interview the child or adolescent. For the 
preschool or young school-age child the interview may be done concurrently with the parent 
interview. Older children and adolescents should be interviewed separately from parents. The 
primary purpose of the interview with the child or adolescent is not to confirm or refute the 
diagnosis of ADHD. Young children are often unaware of their symptoms of ADHD, and older 
children and adolescents may be aware of symptoms but will minimize their significance. The 
interview with the child or adolescent allows the clinician to identify signs or symptoms 
inconsistent with ADHD or suggestive of other serious co-morbid disorders. This is achieved by 
means of a mental status examination, assessing appearance, sensorium, mood, affect, and thought 
processes.  
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Since several medical problems can be associated with ADHD, as previously discussed, the 
general medical examination is indispensable to corroborate some of these conditions35. The 
neurologic examination is part of any complete diagnostic evaluation. In addition to the traditional 
neurologic examination, a number of standardized office examinations that tap developmental 
neurologic functions are available. Furthermore, the neurologic examination provides an 
opportunity to evaluate for commonly co-morbid neurologic problems of coordination like 
dyspraxia, and dysgraphia35.  
Neuropsychological testing is not a necessary part of the diagnostic assessment of ADHD, 
unless specific co-morbid or associated learning issues need to be evaluated. Results of 
neuropsychological testing, however, may lend support to the diagnosis. Although 
neuropsychological testing may be supportive of the ADHD diagnosis, it cannot be used in isolation 
to diagnose ADHD9. Executive functions should be particularly investigated, although deficits in 
executive functioning are by no means always present in ADHD children nor are they unique to 
ADHD. Intelligence should be assessed. Higher IQ ADHD children may compensate for their 
attention difficulties sufficiently to mask executive dysfunction on traditional measures.  
If the patient’s medical history is unremarkable, laboratory or neurological testing is not 
indicated. The measurement of thyroid levels and thyroid-stimulating hormone should be 
considered only if symptoms of hyperthyroidism other than increased activity level are present. 
Exposure to lead, either prenatally or during development, is associated with a number of 
neurocognitive impairments, including ADHD. If a patient has been raised in environment where 
exposure to lead paint or plumbing is probable, then serum lead levels should be considered. Serum 
lead level should not be part of routine screening.  
Unless there is strong evidence of such factors in the medical history, neurological studies 
(EEG), magnetic resonance imaging, SPECT, or PET are not indicated for the evaluation of ADHD. 
Although differences between electroencephalograms, particularly quantitative ones, and evoked 
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responses in ADHD versus controls have been reported, the number and quality of such studies do 
not support the use of these measures for diagnostic purposes9.  
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1.1.6 Outcome 
 
Follow-up studies have begun to delineate the life course of ADHD. A majority (60%-85%) 
of children with ADHD will continue to meet criteria for the disorder during their teenage years 36, 
clearly indicating that ADHD does not remit with the onset of puberty alone. Although only 40% of 
18- to 20-year-old “grown up” ADHD patients met the full criteria for ADHD, 90% had at least five 
symptoms of ADHD and a significant impairment, as indicated by a Global Assessment of 
Functioning score below 60. Adults with a childhood history of ADHD have higher than expected 
rates of antisocial and criminal behaviour37, injuries and accidents37, employment and marital 
difficulties, and health problems and are more likely to have teen pregnancies38 and children out of 
wedlock.  
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1.1.7 Treatment 
The patient’s treatment plan may consist of psychopharmacological and/or behavior 
therapy9. This plan should include parental and child psychoeducation about ADHD and its various 
treatment options, linkage with community supports, and additional school resources as appropriate. 
After reviewing all available evidence, the American Academy of Child and Adolescent Psychiatry9 
concluded that it seems established that a pharmacological intervention for ADHD is more effective 
than a behavioral treatment alone. Behavior therapy may be recommended as an initial treatment if 
the patient’s ADHD symptoms are mild with minimal impairment, the diagnosis of ADHD is 
uncertain, parents reject medication treatment, or there is marked disagreement about the diagnosis 
between parents or between parents and teachers39. Several studies have shown short-term 
effectiveness of behavioral parent training39. No evidence support nonpharmacological 
interventions other than behavior therapy9, including cognitive-behavioral therapy and dietary 
modification. The AACAP practice parameters recommend that the initial psychopharmacological 
treatment of ADHD should be a trial with an agent approved by the Food and Drug Administration 
for the treatment of ADHD. Table 4 lists the currently approved FDA drugs for ADHD.  
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Tab. 4. Medications Approved by the FDA for ADHD (Alphabetical by Class) (From: Pliszka et 
al., JAACAP, 20079). 
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The American Academy of Pediatrics40, an international consensus statement41, and the Texas 
Children’s Medication Project42 have recommended stimulants as the first choice. At present time, 
the following drugs have been approved by FDA: dextroamphetamine (DEX), D and D,L-
methylphenidate (MPH), mixed salts amphetamine, and atomoxetine9. Several randomized 
controlled trials in the past 30 years have consistently reported the effectiveness of stimulants for 
ADHD symptoms (the effect size of stimulant treatment relative to placebo is rather large, 
averaging about 1.0, one of the largest effects for any psychotropic medication9). The physician is 
free to choose any of the two stimulant types (MPH or amphetamine) because evidence suggests the 
two are equally efficacious in the treatment of ADHD. There is at present, no method to predict 
which stimulant will produce the best response in a given patient. The most common side effects of 
stimulants are appetite decrease, weight loss, insomnia, or headache. Less common side effects of 
stimulants include tics and emotional lability/irritability9. 
Atomoxetine is currently considered as a second line pharmacological treatment. Direct 
comparisons of the efficacy of atomoxetine with that of MPH43 and amphetamine9 have shown a 
greater treatment effect of the stimulants, and in a meta-analysis of atomoxetine and stimulant 
studies, the effect size for atomoxetine was 0.62 compared with 0.91 and 0.95 for immediate-release 
and long-acting stimulants, respectively9. However, atomoxetine may be considered as the first 
medication for ADHD in individuals with an active substance abuse problem, comorbid anxiety, or 
tics. Atomoxetine is preferred if the patient experiences severe side effects to stimulants such as 
mood lability or tics. Side effects of atomoxetine that occurred more often than those with placebo 
include gastrointestinal distress, sedation, and decreased appetite. 
If a patient fails to respond to trials of all of these agents after an adequate length of time at 
appropriate doses for the agent as noted in Table 2, then the clinician should undertake a review of 
the patient’s diagnosis of ADHD9. If the diagnosis of ADHD is confirmed, second line non FDA 
approved drugs may be considered, including bupropion, tricyclic antidepressants (TCAs), and alfa-
agonists. These agents may have effect sizes considerably less than those of the approved agents 
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and comparable with the effectiveness of behaviour therapy44. Thus, it may be prudent for the 
clinician to recommend a trial of behavior therapy at this point, before moving to these second-line 
agents. Bupropion may cause mild insomnia or loss of appetite. Extremely high single doses (>400 
mg) of bupropion may induce seizures even in patients without epilepsy. TCAs frequently cause 
anticholinergic side effects such as dry mouth, sedation, constipation, changes in vision, or 
tachycardia. Reduction in dose or discontinuation of the TCA is often required if these side effects 
induce impairment. Side effects of alpha-agonists include sedation, dizziness, and possible 
hypotension. According to the AACAP practice parameters9, if a patient with ADHD has a robust 
response to psychopharmacological treatment and subsequently shows normative functioning in 
academic, family, and social functioning, then psychopharmacological treatment of the ADHD 
alone is satisfactory. On the other hand, if a patient with ADHD has a less than optimal response to 
medication, has a co-morbid disorder, or experiences stressors in family life, then psychosocial 
treatment in conjunction with medication treatment is often beneficial.   
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1.2 Iron metabolism 
1.2.1 Systemic iron  
1.2.1.1 Introduction 
Iron is an element which has the capacity to accept and donate electrons readily, 
interconverting between ferrous (Fe 2+) and ferric (Fe3+) forms45. The ease with which iron can 
gain and lose electrons makes it a useful component of oxygen-binding molecules (i.e., hemoglobin 
and myoglobin), cytochromes and various nonhaem enzymes46. Therefore, iron plays a central role 
in a multitude of biological functions, including cellular respiration, DNA synthesis, and key 
metabolic reactions in neurotransmitter production, collagen formation, and immune system 
function47. 
However, the same facile property that permits iron to gain and lose electrons can result in 
the donation of electrons to oxygen, causing the generation of superoxide anions and the hydroxyl 
radical (Fenton reaction). These oxygen metabolites react readily with biological molecules, 
including proteins, lipids and DNA. Therefore, iron loading can lead to free radical damage46;48. 
Thus, since both iron deficiency and iron overload are deleterious45, the challenge for most 
organisms is to acquire adequate amounts of iron for critical biological processes yet avoid the 
toxicity associated with free iron49. Consequently, all mammalian species tightly regulate the 
concentration of iron on both the systemic and the cellular levels46;50. To achieve this, at the 
systemic level, a complex system of  proteins involved in iron uptake, utilisation, storage and export 
is present51. The control of systemic iron levels occurs through a meticulous regulation of iron 
acquisition and storage because in the million years of evolution, nature has not developed a 
regulated pathway for excretion of iron in humans46.  
The last decade has seen a rapid advancement of knowledge in iron metabolism. Modern 
techniques in molecular biology and biochemistry are giving new insights through the identification 
and characterization of proteins involved in iron homeostasis47.  
 
 32 
1.2.1.2 Iron distribution in the body 
 
In the body, iron is distributed in three pools: functional, storage and transport.  
The distribution of iron in human tissues is shown in Fig. 1. 
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Fig. 1. Distribution of iron in human tissue (from Andrews, NEJM, 199945). 
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Adult men normally have 35 to 45 mg of iron per kilogram of body weight. Premenopausal 
women have lower iron stores as a result of their recurrent blood loss through menstruation45.   
About 0.1% of total body iron is circulating (bound to transferrin). Nearly 80% of iron is 
incorporated into hemoglobin in developing erythroid precursors and mature red cells. 
Approximately 10–15% is present in muscle fibers (myoglobin) and in other tissues as enzymes and 
cytochromes (functional iron)47.  
In the balanced state, 1 to 2 mg of iron enters and leaves the body each day45 . 
Approximately 1 to 2mg of iron is lost each day by epithelial shedding in the gastrointestinal tract 
and the skin and through blood loss in menstruating women. There is no physiologic mechanism for 
excreting larger amounts of iron, even in severely iron-overloaded individuals. The normal losses 
are balanced by absorption of iron from the diet. Western diets contain a much greater amount of 
iron (10 to 20 mg) than what is absorbed daily under normal circumstances (1 to 2 mg). 
Iron absorption increases several-fold in iron deficiency and is suppressed partly when iron stores 
are excessive49.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 35 
1.2.1.3 Iron absorption 
 
Iron absorption occurs predominantly in the apical surface of the duodenum and upper 
jejunum. The two forms of dietary iron, i.e. heme and non-heme iron, are absorbed by the 
enterocyte non-competitively. In diets rich in meat, heme accounts for approximately two-thirds of 
the dietary iron supply of the body50.  
Inorganic, nonheme iron is inefficiently absorbed but present in a wide variety of foodstuffs. 
Heme iron is more efficiently absorbed, primarily from animal sources in the form of hemoglobin 
or myoglobin49. 
Because there is little or no paracellular iron transport under normal circumstances, iron 
must traverse both the apical and basolateral membranes to gain access to the circulation49.  
A membrane protein called heme carrier protein 1 (HCP1) mediates heme uptake by cells. HCP1 is 
expressed at high levels in the duodenum52 and, upon binding of heme to HCP1 on the cell surface, 
the complex is internalized by receptor-mediated endocytosis. The resultant endosomal vesicles 
migrate to the endoplasmic reticulum, where iron is liberated from heme by the heme oxygenase-1 
(HO1) that is found on the reticulum surface.  
The non-heme iron mainly exists in the Fe3+ state. The ferric iron is reduced to ferrous iron 
by dietary components and duodenal cytochrome b reductase (Dcytb) which is highly expressed in 
the brush border of enterocytes52. Once the insoluble Fe3+ is converted to Fe2+, it enters the 
mucosal phase. However, ablation of the murine Dcytb homolog Cybrd1 results in no iron-deficient 
phenotype, suggesting that Dcytb is not essential for dietary iron uptake in the mouse and that 
another ferrireductase remains to be discovered53.  Fe2+ is transported across the apical membrane 
into the cell through a divalent metal transporter (DMT1). DMT1 is expressed at the duodenal brush 
border where it controls uptake of dietary iron. A pathway for Fe3+ transport has also been 
proposed, where it is transported as an integrin–mobilferrin (IM) complex across the enterocyte. 
The Fe3+ is then converted to Fe2+ by the inherent ferrireductase activity of paraferritin54. 
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Iron liberated from heme or imported into the enterocyte by DMT1 then enters the hypothesized 
intracellular or ‘labile’ iron pool. The molecular character of this pool in enterocytes remains 
unknown, but it could consist of low molecular weight chelates or chaperone proteins that bind and 
transport iron55. Some of the iron extracted from the diet is stored in ferritin within the enterocyte, 
and some is exported across the enterocyte’s basolateral membrane. The retained iron is lost after 
two to three days owing to the sloughing of enterocytes into the gut lumen.  
The Fe2+ inside the cell can undergo two fates: either it can be stored as ferritin or 
transported across the basolateral surface into the blood stream by a transport protein called 
ferroportin (FPN)56;57. Ferroportin likely conducts Fe2+ ions. Cellular iron export requires an 
associated ferroxidase activity. In the intestine, ceruloplasmin, a circulating multicopper oxidase, 
and hephaestin, a homolog of ceruloplasmin, appear to supply this activity. The precise site of 
ferroxidase activity remains uncertain, but Fe2+ must be oxidized to Fe3+ by hephaestin to circulate 
bound to plasma proteins49.  
Studies have shown that plant and animal ferritin can also be absorbed in the intestine58;59. 
Receptors for lactoferrin, an iron binding protein, are found in fetal enterocytes. Lactoferrin is 
viewed as the primary source of iron in infants and it may be a source in adult females also60. 
Fig. 2 illustrates iron transport across the enterocyte. 
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Fig. 2. Iron transport across the enterocyte (from De Domenico et al., Nature Reviews, Molecular 
Cell Biology, 200846) . 
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1.2.1.4 Delivery of iron to tissues 
Absorbed iron is rapidly bound to transferrin (TF), an abundant, high affinity iron-binding 
protein49. Under normal circumstances, TF carries nearly all serum iron. Very small amounts of iron 
may be loosely associated with albumin or small molecules. In normal human subjects, iron 
occupies approximately 30% of the iron-binding sites on plasma TF. The saturation of TF by iron 
varies on a diurnal cycle and rapidly responds to local circumstances61. It is likely to be higher in 
the portal circulation, where recently absorbed iron from the intestine enters the circulation and 
passes through the liver49. Conversely, TF saturation is likely lower than average in plasma leaving 
the erythroid bone marrow, where most of the iron present is extracted for use by erythroid 
precursor cells49. Binding of iron to transferrin limits the ability of iron to generate toxic radicals. 
Then,  transferrin directs iron towards cells that express transferrin receptors46. The transferrin–Fe 
(III) complex in plasma is transported into cells through one of two cell-surface transferring 
receptors. Transferrin receptor R-1 is expressed on all dividing cells and is particularly enriched on 
precursors of the erythron because these cells show the highest demand for iron. Transferrin R-2 is 
expressed primarily in the liver and binds the transferrin–Fe(III) complex at a much lower affinity 
than transferrin R-1 does46. After binding to its receptor, the complex of Fe(III)-transferrin-
transferrin R- is rapidly internalized by receptor-mediated endocytosis through clathrin-coated pits 
(Fig. 3).  
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Fig. 3. Endocytosis of the complex of iron, transferrin and the transferring receptor (from De 
Domenico et al., Nature Reviews, Molecular Cell Biology, 200846). 
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Inside the cells, the internalized complex localizes to an endosome that is acidified by an AT 
dependent proton pump that lowers the luminal pH to ~5.5. Acidification produces a 
conformational change in both transferrin–Fe(III) and transferrin R-1 with the consequent release of 
iron. The endosomal Fe(III) is converted into Fe(II) by a ferrireductase that has been identified as 
STEAP3. Endosomal DMT1 transports the product of the STEAP3-catalysed reaction from the 
endosome to the cytosol. At acidic pH, apotransferrin remains bound to transferrin R-1 and the 
complex is recycled to the cell surface. At the more neutral pH of plasma, apotransferrin dissociates 
from transferrin R-1 and is free to bind iron and initiate further rounds of receptor-mediated 
endocytosis62;63. 
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1.2.1.5 Iron utilization 
The erythroid bone marrow is the largest consumer of iron. Normally, two-thirds of the body 
iron endowment is found in developing erythroid precursors and mature red blood cells49. Although 
TFRs are widely expressed, most other cells apparently can use non-TFR mechanisms to assimilate 
iron; it is not clear why hematopoietic cells remain so dependent upon the TF cycle. Once iron 
leaves the endosome, it must move to the mitochondrion for incorporation into protoporphyrin IX 
by ferrochelatase to form heme. Heme biosynthesis begins and ends in the mitochondrion, but 
intermediate steps occur in the cytoplasm49. Mitoferrin (also known as SLC25A37) carries out 
mitochondrial iron import65. Murine mitoferrin is a homolog of the zebrafish protein frascati and the 
yeast proteins MRS3 and MRS465. Although muscle cells also require large amounts of iron to 
produce myoglobin, far less is known about how they assimilate iron49. It is not clear whether 
mitoferrin is also involved in mitochondrial iron uptake in muscle and other nonhematopoietic 
tissues. Heme is then transported out of the mitochondrion for insertion into protein, such as 
cytochromes. However, the heme transporters(s) responsible for heme release remain unclear.48 
Three molecules have been identified as possible mitochondrial heme exporters or transporters: the 
breast cancer resistance protein (ABCG2)66, the ABC-mitochondrial erythroid (ABC-me) 
transporter64 and the feline leukemic virus subgroup C receptor (FLVCR)65. 
TFR plays an important, but poorly understood, role in lymphopoiesis. It has been shown 
that TFR is a marker of lymphocyte but is not clear whether TFR is needed for accelerated iron 
uptake by rapidly proliferating cells or for a different, unrelated function66. 
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1.2.1.6 Iron recycling and storage 
Intestinal absorption accounts for only a fraction of iron circulating bound to TF. Because 
there is no known regulated mechanism for iron excretion, and the amount of iron entering the body 
each day represents less than 0.1% of the total body iron endowment, most circulating iron must be 
derived from the recycling of iron already within the system. Quantitatively, recovery of iron from 
senescent erythrocytes contributes the most. Old and damaged erythrocytes are phagocytosed by 
tissue macrophages, particularly in the spleen. The cells are lysed, and hemoglobin is catabolized, 
presumably by heme oxygenase, to liberate iron. Some iron remains in storage in macrophages, 
although some is exported to plasma TF. FPN is critical for macrophage iron export and can be 
regulated to change the ratio between stored and released iron49. Hepatocytes also serve as depots 
for iron storage, but they acquire their iron load in a different fashion. Although the TF cycle may 
be involved in hepatocyte iron acquisition to some extent, non–transferrin-bound iron (NTBI) 
uptake pathways become particularly important when serum iron levels exceed TF binding 
capacity49. 
The identity of the hepatocyte NTBI uptake system is not known. Candidates for the NTBI 
transporter include L-type calcium channels70, transient receptor potential canonical protein 
TRPC667, and transporters already identified for their ability to transport other metal ions. 
Hepatocytes have a large capacity to store excess iron. Most storage iron is probably in the form of 
ferritin, which can be mobilized when needed elsewhere in the body. The substrate for ferritin is 
Fe(II), which is oxidized to Fe(III) within the ferritin shell, and Fe(III) is stored with ferritin. 
Ferritin is a multimer of 24 subunits comprised of H (for heavy or heart) and L (for light and liver) 
protein subunits68. Ferritin shells show different combinations of the two subunits depending on the 
tissue in which they are expressed. The liver and spleen are rich in L subunits, whereas the heart is 
rich in H subunits. 
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1.2.1.7 Iron deficiency 
If one considers that there is no physiologic pathway for iron excretion, it is easy to 
understand that  iron deficiency (ID) will result from any condition in which dietary iron intake 
does not meet the body’s demands. For this reason, rapidly growing children and premenopausal 
women are at highest risk. Worldwide, dietary insufficiency as a cause of iron deficiency is usually 
secondary to intestinal blood loss resulting from parasitosis. In such cases, dietary intake is unable 
to keep up with chronic losses. Tab. 5 summarizes the most common causes of iron deficiency, 
which are reviewed in detail and discussed in the recent paper by Borgna-Pignatti and Marsella69. 
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Tab. 5. Causes of iron deficiency (from Andrews, NEJM, 199945). 
_______________________________________________________________________________  
Inadequate absorption 
Poor bioavailability 
Antacid therapy or high gastric pH 
Excess dietary bran, tannin, phytates, or starch 
Competition from other metals (e.g., copper or 
lead) 
Loss or dysfunction of absorptive enterocytes 
Bowel resection 
Celiac disease 
Inflammatory bowel disease 
Intrinsic enterocyte defects 
 
Increased loss 
Gastrointestinal blood loss 
Epistaxis 
Varices 
Gastritis 
Ulcer 
Tumor 
Meckel’s diverticulum 
Parasitosis 
Milk-induced enteropathy of early childhood 
Vascular malformations 
Inflammatory bowel disease 
Diverticulosis 
Hemorrhoids 
Genitourinary blood loss 
Menorrhagia 
Cancer 
Chronic infection 
Pulmonary blood loss 
Pulmonary hemosiderosis 
Infection 
Other blood loss 
Trauma 
Excessive phlebotomy 
Large vascular malformations 
________________________________________________________________________________  
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During the development of iron deficiency, the human body prioritizes the use of iron in 
several ways. The erythron has relative priority as compared with other tissues. Red-cell production 
is unperturbed until iron stores are depleted, as reflected by low serum ferritin levels. The 
development of iron deficiency is gradual.  
Depletion of iron stores is the first step. At the beginning, iron is still available for 
erythropoiesis. When the stores have been used up, the iron saturation of transferrin (a protein 
which transports iron in the plasma, as we will explain below) decreases and when its value is less 
than 15%, patients begin to show evidence of iron-deficient erythropoiesis. The first biochemical 
clues of iron deficiency are increased levels of free protoporphyrin and zinc protoporphyrin in 
erythrocytes. The levels of soluble transferrin receptor, a protein-cleavage product that is present in 
plasma, increase when the lack of iron limits the production of new red cells. Frank anemia with 
microcytosis is detected later. 
On the basis of the temporal course and characteristics of iron deficiency, iron deficient 
states are defined in the following way: 
1. Iron deficiency (ID) is a reduction in body Fe to the extent that cellular storage Fe required for 
metabolic/physiological functions is fully exhausted, with or without anaemia. 
2. Iron deficiency anaemia (IDA) is defined as ID and a low haemoglobin (Hb). 
3. Iron-deficient erythropoiesis (IDE) is defined as laboratory evidence of a reduced supply of 
circulating Fe for erythropoiesis, indicated by either reduced Fe saturation of plasma transferrin or 
signs of ID in circulating erythrocytes. IDE is not synonymous with ID or IDA; IDE can occur 
despite normal or even increased storage Fe, due to impaired release of Fe to the plasma(21). IDE is 
often associated with malignancy or inflammation. 
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1.2.1.8 Iron regulation 
Regulation of cellular iron  
Individual cells must maintain internal iron homeostasis to ensure that there is adequate iron 
for basal functions but no free iron that could promote formation of reactive oxygen species. Cells 
accomplish this by at least two mechanisms:  
First, all mammalian cells produce ferritin, an iron storage protein. Each ferritin polymer can 
accommodate up to 4500 iron atoms. Ferritin acts as a depot, accepting excess iron and allowing for 
the mobilization of iron when needed49. 
The second protective mechanism involves iron regulatory proteins (IRPs), which, when 
iron is limiting, bind to RNA stem-loop iron regulatory elements (IREs) found in the untranslated 
regions of mRNAs involved in iron transport and storage. Two IRPs have been identified: IRP1 
(approved gene symbol ACO1) and IRP2 (approved gene symbol IREB2)51. IRP1 can incorporate 
an iron-sulfur cluster, which acts as an iron sensor70. IRP2 does not contain an ironsulfur cluster, 
but it is rapidly ubiquinated and degraded in the presence of excess iron71. The binding of IRPs to 
IREs serves either of two purposes, depending upon the location of the IREs. IRP binding to IREs 
found in the 5’ untranslated regions of mRNAs encoding ferritin, sterically blocks the initiation of 
translation, thus stopping the production of ferritin when iron storage would be counterproductive. 
On the other hand, IREs found in the 3’ untranslated region of TFR1 stabilizes the molecule, thus 
allowing more TFR1 to be produced when iron is limiting. However, the roles of IREs and IRPs in 
vivo remain uncertain. IRP1. IRP2 binds consensus IRE sequences with an affinity and specificity 
similar to that of IRP1 (Refs 2, 5), but it has been shown to recognise an exclusive subset of IRE-
like motifs51. IRP2 is specifically modulated in response to stimuli and agents other than iron, such 
as hypoxia and is more sensitive than IRP1 to variations of iron in the diet, is expressed at high 
levels in most cell lines and, when abundantly or uniquely expressed, can act as the major or only 
modulator of intracellular iron metabolism, as also indicated by studies in cells in which either 
IRP1, IRP2 or both were knocked down51. Mice lacking either IRP1 or IRP2 are viable, thus 
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indicating that the two IRPs can compensate for each other. Over the past decade it has been shown 
that other genes involved in iron uptake, release and utilisation are also controlled by the IRE–IRP 
regulatory network51. In addition to modulating ferritin and TFR1 levels, IRPs can regulate the 
mRNAs for other proteins. IRE structures have been detected in several mRNAs encoding proteins 
related to iron utilisation (eALAS; mitochondrial aconitase, approved gene symbol ACO2; 
succinate dehydrogenase, gene symbol SDHB), uptake [divalent metal transporter 1 (DMT1), 
official symbol SLC11A2] and release (ferroportin, gene symbol SLC40A1)51. 
Regulation of systemic iron balance 
Iron balance must be meticulously regulated to provide iron as needed but avoid the toxicity 
associated with iron excess.  
The regulation of systemic iron metabolism involves iron absorption but also macrophage iron 
recycling and hepatocyte iron mobilization.  
For several days after a dietary iron bolus, absorptive enterocytes are resistant to acquiring 
additional iron. This phenomenon has previously been called “mucosal block.” This blocking action 
probably results from the accumulation of intracellular iron, leading the enterocyte to believe that 
its set-point requirements have been met. It may occur even in the presence of systemic iron 
deficiency. A second regulatory mechanism also senses iron levels but responds to total body iron, 
rather than dietary iron. This mechanism has been termed the stores regulator. It is capable of 
changing the amount of iron absorbed to a limited extent: iron absorption is modulated by a factor 
of only two to three in iron deficient states as compared with iron-replete states. Although the 
molecular details of the stores regulator are not known, it probably acts at the level of crypt-cell 
programming, in response to the saturation of plasma transferrin with iron. The third regulatory 
mechanism, known as the erythropoietic regulator, does not respond to iron levels at all. Rather, it 
modulates iron absorption in response to the requirements for erythropoiesis. Thus, the stimuli 
known to modulate the iron homeostatic mechanism are erythroid iron needs, hypoxia, iron 
deficiency, iron overload, and inflammation. 
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Hepcidin, a circulating peptide hormone, controls much of systemic iron regulation72. 
Hepcidin expression is altered in response to each of the stimuli known to affect iron homeostasis: it 
is increased in response to increased serum iron, iron overload, and inflammation and diminished in 
response to increased erythroid drive, hypoxia, and iron deficiency49. Hepcidin interrupts cellular 
iron export in at least two sites: the intestinal epithelium and tissue macrophages by binding directly 
to ferroportin and triggering its internalization and degradation within lysosomes73. Under basal 
conditions, hepcidin expression depends upon signaling through a bone morphogenetic protein. 
Regulation of hepcidin also occurs in inflammatory conditions. Interleukin-6 (IL-6) and possibly 
other inflammatory cytokines induce transcription of the hepcidin gene in hepatocytes in vitro and 
in vivo74. There are 3 sites in the mammalian body that are excluded from the liver-dependent 
macroregulatory axis: the central nervous system (CNS), testis, and retina75. 
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1.2.1.9 Assessment of peripheral iron status 
Tissue iron concentrations 
 
The liver and bone marrow are important and relatively accessible storage sites and the 
amount of iron present in a tissue biopsy can be estimated either visually, using the Prussian blue 
reaction on tissue sections, or chemically. There is generally a good correlation between iron 
concentrations in liver and bone marrow. Assessing marrow iron histologically distinguishes 
between 'true' iron deficiency and other chronic disorders in which there is impaired release of iron 
from reticuloendothelial cells76. 
Therefore, bone-marrow examination to establish the absence of stainable iron remains the 
gold standard for the diagnosis of iron deficiency, particularly when performed and reviewed under 
standardized conditions by experienced investigators. However, marrow examinations are 
expensive, uncomfortable, and require technical expertise, and are not performed routinely in 
clinical practice77. 
Haemoglobin 
Haemoglobin (Hb) is a widely used screening test for ID, but used alone has low specificity 
and sensitivity. Its sensitivity is low because individuals with baseline Hb values in the upper range 
of normal need to lose 20–30% of their body Fe before their Hb falls below the cut-off for 
anaemia78. Its specificity is low because there are many causes of anaemia other than ID. Cut-off 
criteria differ with the age and sex of the individual, between laboratories, and there are ethnic 
differences in normal Hb79;80. 
Mean corpuscular volume and reticulocyte Hb content (CHr) 
 
Measured on widely-available automated haematology analysers, the mean corpuscular 
volume (MCV) is a reliable, but relatively late indicator of ID, and its differential diagnosis 
includes thalassemia. The reticulocyte Hb content has been proposed as a sensitive indicator that 
falls within days of the onset of IDE81. However, false normal values can occur when the MCV is 
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increased or in thalassemia; its wide use is limited as it can only be measured on one model of 
analyzer. For both MCV and CHr, low specificity limits their clinical utility82. 
Erythrocyte zinc protoporphyrin 
 
Erythrocyte zinc protoporphyrin (ZnPP) increases in IDE because zinc replaces the missing 
iron during formation of the protoporphyrin ring83. Therefore, ZnPP may also be a sensitive test for 
detecting iron deficiency. However, the specificity of ZnPP in identifying iron deficiency may be 
limited, because ZnPP can be increased by lead poisoning, anaemia of chronic disease, chronic 
infections and inflammation, haemolytic anaemias, or haemoglobinopathies77. 
Transferrin saturation 
 
Transferrin saturation is a widely used screening test for iron deficiency, calculated as the 
ratio of plasma Fe to total Fe-binding capacity. Although relatively inexpensive, its use is limited by 
diurnal variation in serum iron and transferrin (transferring shows a diurnal variation ranging from 
17 to 70%84) as well as the many clinical disorders that influence transferrin levels78. 
Serum ferritin 
Serum ferritin (SF) may be the most useful laboratory measure of iron status; a low value is 
diagnostic of iron deficiency anemia in a patient with anaemia. In healthy individuals, SF is directly 
proportional to iron stores. It is widely available, well-standardized, and has repeatedly been 
demonstrated to be superior to other measurements for identifying iron deficiency anemia. Serum 
ferritin concentrations are normally within the range 15-300 mcg/l (this is a “statistical” range; we 
will discuss the issue of the clinical implication of a cut-off value of serum ferritin later in the 
thesis). Values are lower in children than adults, and from puberty to middle age mean 
concentrations are higher in men than in women. Good correlations have been found between serum 
ferritin concentrations and storage iron mobilised by phlebotomy, stainable iron in the bone marrow 
and the concentration of both non-haem iron and ferritin in the bone marrow. In patients with iron 
deficiency anaemia, serum ferritin concentrations are less than 12-15 mcg/1 (depending on the 
assay) and a reduction in the level of reticuloendothelial stores is the only common cause of a low 
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serum ferritin concentration76. This is the key to the use of the serum ferritin assay in clinical 
practice. However, because it is an acute phase protein, SF is increased independent of Fe status by 
acute or chronic inflammation. It is also unreliable in the setting of malignancy, hyperthyroidism, 
and heavy alcohol intake77. The other major influence confounding the use of the serum ferritin 
assay to determine iron stores is liver disease. The liver contains much of the storage iron in the 
body and any process that damages liver cells will release ferritin. Starvation, or even fasting for a 
short period, can elevate the serum ferritin concentration and vitamin C deficiency may reduce it76.  
Red cell ferritin 
 
The ferritin in the circulating erythrocyte is a residue of that present in its nucleated 
precursors in the bone marrow. Red cell ferritin levels reflect the iron supply to the erythroid 
marrow and tend to vary inversely with red cell free-protoporphyrin levels. Red cell ferritin levels 
do not therefore necessarily indicate levels of storage iron76. High levels of red cell ferritin are 
found in thalassaemia, megaloblastic anaemia and myelodysplastic syndromes, indicating the 
disturbance of erythroid iron metabolism associated with abnormalities in globin synthesis in these 
conditions. Because it is necessary to have fresh blood in order to prepare red cells free of white 
cells (which have much higher ferritin levels) the assay of red cell ferritin has seen little routine 
application despite possible diagnostic advantages. 
Serum transferrin receptor 
The serum transferrin receptor (TfR) is a transmembrane glycoprotein that transfers 
circulating Fe into developing red cells. A circulating, soluble form of TfR consists of the 
extracellular domain of the receptor. Serum TfR concentration appears to be a specific indicator of 
IDE that is not confounded by inflammation85. In normal subjects the serum transferrin receptor 
level also provides a sensitive indicator of functional iron deficiency in subjects with absent iron 
stores but who have not yet developed iron deficiency anaemia76. However, normal expansion of 
the erythroid mass during growth, as well as diseases common in developing countries, including 
thalassemia, megaloblastic anaemia due to folate deficiency, or hemolysis due to malaria, may 
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increase erythropoiesis and TfR independent of iron status. Thus, the diagnostic value of TfR for 
iron deficiency anemia is uncertain in children from regions where inflammatory conditions, 
infection and malaria are endemic86. 
TfR/SF ratio 
 
The ratio of TfR/SF can be used to quantitatively estimate total body Fe78. The logarithm of 
this ratio is directly proportional to the amount of stored Fe in Fe-replete subjects and the tissue Fe 
deficit in ID. However, it cannot be used in individuals with inflammation because the SF may be 
elevated independent of iron stores, and is assay specific. 
Quantitative phlebotomy 
 
A direct way of measuring iron stores is by quantitative phlebotomy (removing up to 500 ml 
blood week until anaemia develops). This gives a measure of the amount of iron available for 
haemoglobin synthesis. Quantitative phlebotomy has been applied to validate the concept that 
serum ferritin concentrations in normal subjects reflect the level of available storage iron76. 
Non-invasive methods for determining tissue iron concentrations 
Magnetic resonance imaging is a widely available technique which has been applied to the 
determination of liver and heart iron concentrations76. We will discuss extensively the use of MRI 
to assess brain iron status later in the thesis. 
Assessing iron status using multiple indices 
The major diagnostic challenge is to distinguish between IDA in otherwise healthy 
individuals, and the anaemia of chronic disease (ACD)77. The distinction between ACD and IDA is 
difficult, as an elevated SF in anaemia does not exclude IDA in the presence of inflammation. A 
widely-used marker of inflammation is the C-reactive protein (CRP). If anaemia is present and the 
CRP is elevated, IDA can usually be diagnosed in individuals with inflammatory disorders/anaemia 
of chronic disease by an elevated TfR and/or ZnPP. However, it has recently been pointed77 out that 
sensitivity and specificity of TfR and ZnPP in identifying iron deficiency and IDA in children is 
modest, regardless of the diagnostic cut-offs chosen, because of the overlap in the distributions of 
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these indicators in a comparison of children with IDA with those with normal iron status. Because 
each test of iron status has limitations in terms of its sensitivity and specificity, they have been 
combined in models to define iron deficiency. Examples include the model based on low transferrin 
saturation and high ZnPP, and the ferritin model based on low SF and transferrin saturation and 
high ZnPP. With these models, specificity increases but sensitivity is low, and they tend to 
underestimate ID. When it is feasible to measure several indices, the best  combination is usually 
Hb, SF and, if CRP is elevated, TfR and/or ZnPP77. Overlap in laboratory values between anaemic 
and non-anaemic individuals means that using haemoglobin measurements alone leads to an 
overestimate of the prevalence of iron deficiency anaemia. Similarly, the use of only one indicator 
of storage iron levels or tissue iron supply - ferritin, transferrin saturation or erythrocyte 
protoporphyrin - may overestimate the number of individuals with absent iron stores. Cook et al.87 
showed that lower figures for the prevalence of iron deficient erythropoiesis and iron deficiency 
anaemia were obtained by using multiple criteria (abnormal values for any two of serum ferritin, 
transferrin saturation or erythrocyte protoporphyrin). 
Methodological and biological variability of assays 
 
The blood assays vary greatly in both methodological and biological stability. Haemoglobin 
concentrations are stable and the simple and well standardised method of determination ensures 
relatively low day-to-day variation in individuals76. The more complicated immunoassays for 
ferritin have higher methodological variation (coefficient of variation, CV, of at least 5%) and this, 
coupled with some physiological variation, gives an overall CV for serum ferritin for an individual 
over a period of weeks of the order of 15%. There is little evidence of any significant diurnal 
variation in serum ferritin concentration. Serum iron shows high physiological variability giving an 
overall 'within subject' CV of approximately 30% when venous samples are taken at the same time 
of day. Moreover, serum iron concentrations are generally higher in the morning than in late 
afternoon.  
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There is no information on seasonal factors influencing most of these analyses although 
seasonal changes in red cell parameters have been reported76. 
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1.2.2 Brain iron 
 
1.2.2.1 Introduction 
A number of recent studies, especially the new discovery of mutations in the genes 
associated with brain iron metabolism, have made important contributions to our understanding of 
homeostatic mechanisms of brain iron metabolism88. In this section, we summarize recent advances 
in studies on physiological aspects of brain iron metabolism. 
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1.2.2.2 Iron transport into the brain 
Iron transport across the blood–brain barrier (BBB) 
For many years, it was believed that iron entered the brain mainly during infancy before the 
blood-brain barrier (BBB) matured. However, in the last decade, it has become apparent that brain-
iron uptake is possible throughout the BBB of adult animals75.  
How iron crosses the BBB has not been completely clarified. Available data suggest that the 
transferrin/transferrin receptor (Tf/TfR) pathway may be the major route of iron transport across the 
luminal membrane of the capillary endothelium88;89. It has been hypothesized that the uptake of 
transferring-bound iron (Tf-Fe) by TfR-mediated endocytosis from the blood into cerebral 
endothelial cells includes several steps: 1. Binding of Tf to the extracellular portion of TfR; 2. 
Endocytosis of the complex of iron–Tf–TfR and formation of endosome; 3. Acidification of the 
microenvironment within endosome; 4. Dissociation of iron from Tf and reduction of Fe3+ to Fe2+; 
5. Translocation of iron (Fe2+) across the endosomal membrane probably by a divalent metal 
transporter 1 (DMT1, previously referred to as Nramp2 or DCT1)-mediated process90. Most of the 
Tf will return to the luminal membrane with TfR. However, Moos and colleagues91 pointed out that 
DMT1 is absent from brain capillary endothelial cells. They suggest that transferrin receptor-
containing vesicles are transported through the brain capillary endothelial cells (BCECs) and fuse 
with the abluminal side, thus offering  iron detached from transferrin and ready to be transported 
further into the brain. According to Moos et al.91, the released iron atoms would probably be in their 
ferric form, and the process would not require the function of ferroportin. Indeed, in vitro studies of 
BCECs grown in polarized conditions do indicate that transferrin-containing vesicles fuse with the 
abluminal surface, confirming the hypothesis of Moos and co-workers91. Moreover, the astrocytes 
probably have the ability to take up Fe2+ from endothelial cells through their end feet processes on 
the capillary endothelia. Moos and colleagues91 proposes that the low Ph microenvironment of the 
abluminal surface of  BCECs  contributes to the release of iron from transferring. ATP and other 
nucleotides are released from astrocytes and other brain cells 94-96 and could act as mediators of iron 
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release from transferrin. Also, citrate, another such mediator, is released from astrocytes92 and is 
present in brain interstitial fluid in relatively high concentrations (Fig 4). The transferrin would 
mainly remain bound to its receptor which has a high affinity for apotransferrin at acidic pH93 and 
would recycle to the plasma. The iron would pass into the brain interstitium to be bound by citrate, 
ascorbate94 or the transferrin present in the interstitial fluid.  
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Fig. 4. Transport of iron across the brain capillary according to Moos et al. (from Moos et al., J 
Neurochem, 200791).  
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On the contrary, Siddapappa et al. reported the presence of DMT1 in BCECs95;96. This may 
be consistent with an export of iron across the abluminal membrane of BCECs by means of 
ferroportin 1 (FP1)/ hephaestin (Hp) and/or hephaestin-independent (FP1/CP) iron export systems, 
similarly to the process of export found in the enterocytes. Indeed, a number of recent studies have 
confirmed that the brain, including capillary endothelium of the BBB, neurons and astrocytes, has 
the ability to express FP1 and Hp97-101 although one study did not find evidence of FP1 in brain 
capillary endothelial cells102 (Fig. 5). 
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Fig. 5. Transport of iron across the brain capillary according to Rouault et al. (from Rouault and 
Cooperman, 200675)  
 
 
 
The blood-brain barrier is composed of endothelial cells joined by tight junctions surrounded by a 
basement membrane in which pericytes are found and which is in close apposition with astrocytic 
foot processes. TfR1 is expressed on the lumenal membrane of endothelial cells, which have nuclei 
(N) and which likely express ferroportin (cylinders). Astrocytic foot processes express GPI-linked 
ceruloplasmin (lightening). On endocytosis of the Tf- TfR complex, ferric iron (dots) is reduced to 
ferrous iron (pale dot); exported to cytosol, most likely by DMT1; exported from the cell, 
presumably by ferroportin; and oxidized to ferric iron by GPIlinked ceruloplasmin within brain 
interstitium. Transferrin synthesized by oligodendrocytes in the brain binds ferric iron, and neurons 
and probably many other brain cells acquire iron by expressing the TfR, although TfR expression is 
low in nonneuronal cells. To exit the brain interstitial fluid and cerebrospinal fluid, iron must cross 
the arachnoid membrane (not shown), a tight epithelial layer that brain Tf does not cross. 
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Therefore, given the contrasting findings on the modalities of iron export from BCECs, this issue 
needs further investigation. 
Moreover, the lactoferrin receptor (LfR)/lactoferrin (Lf103) and GPI-anchored 
melanotransferrin (MTf)/soluble melanotransferrin (sMTf)104 pathways might play a role in iron 
transport across the BBB. It is also possible that a small amount of iron might cross the BBB in the 
form of intact Tf-Fe complex by receptor mediated transcytosis105. The existence of the a non- 
transferrin binding iron transport across the BBB cells has also been reported106. 
 
Iron transport across the blood–cerebrospinal fluid barrier 
 
Choroid plexus epithelial cells simultaneously constitute a barrier: the blood–cerebrospinal 
fluid (CSF) barrier (the blood–CSF barrier) for circulating plasma proteins from the brain112;113. 
A major difference between the choroid plexus (blood–CSF barrier) and the brain endothelium 
(BBB) barrier is that the choroid plexus of the lateral and third ventricle synthesize Tf, which may 
be of importance for the transport of iron across the choroid plexus88. However, available studies 
indicate that the contribution of iron transported through the blood–CSF barrier to the brain may be 
negligible as compared to that transported through the BBB. It is possible that the blood–CSF 
barrier is more useful for iron removal from brain other than iron transport into the brain. 
Iron transport by the circumventircular organs  
The circumventircular organs that receive neuronal projections, mainly from hypothaalmic nuclei, 
have been suggested to play a role for iron transport in the developing brain. Some motor neurons 
that project to peripheral organs devoid of blood barrier express TfR and retrograde axonal transport 
iron into brain107. The physiological significance of bypassing the brain barrier iron transport 
deserves further investigation.  
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1.2.2.3 Iron transport within the brain 
After the iron has been transported across the BBB or blood– CSF barrier most of iron (Fe2+) will 
be oxidized to Fe3+ and then bind to Transferrin (Tf) before being acquired by brain cells99;115;116. It 
has been reported that the main source of brain transferrin is represented by oligodendrocytes108. 
Unlike Tf found in blood, Tf in CSF and IF is fully saturated with iron. The excess iron will bind to 
other transporters. Hence, it is possible that there are two transport forms of iron in CSF and IF in 
the brain: Tf-Fe and NTBI99;116. The latter probably includes citrate-Fe3+ or Fe2+, ascorbate-Fe2+, 
and albumin-Fe (2+ or 3+) and also Lf-Fe3+ and sMTf-Fe3+. The Tf-Fe or probably Lf-Fe and 
sMTf-Fe will be taken up by brain cells via TfR or LfR and GPI-anchored MTf-mediated processes, 
respectively109;110. NTBI will be acquired by neuronal cells or other brain cells, probably via DMT1 
(iron carrier) or trivalent cation-specific transporter (TCT)111-mediated mechanisms112. However, 
the relevant mechanisms have not yet been detailed. In neurons, the internalization of Tf is followed 
by detachment of iron within recycling endosome and transport into the cytosol via DMT1. 
Moreover, the presence of LfR on neurons indicates that a Lf/LfR-mediated pathway may be 
involved in iron uptake by neurons. TfR mediated endocytosis has been anticipated to be involved 
in Fe3+ uptake in oligodendocytes108;113. In addition, based on the recent identification of a ferritin 
receptor (FtR) predominantly on oligodendrocytes, it has been suggested that these cells may obtain 
iron via ferritin/FtR pathway114;115. It has yet to be determined whether oligodendrocytes can take 
up iron by interchanging with the axon of vicinity neurons. In the astrocytes, the existence of TfR 
expression and TfR-mediated iron uptake has been reported125;126. However, little is known about 
the relevant molecular mechanisms. Several findings suggest that GPI-anchored MTf 
(melanotransferrin receptors) may deliver iron across the BBB by a mechanism analogous to that 
mediated by the TfR, and play a role in iron uptake by microglial cells109. The presence of DMT1 
on astrocytic endfeet in the cerebral cortex and hippocampus of monkeys suggests that astrocytes 
may take up iron from endothelial cells through DMT1116. 
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Neurons are thought to regulate their iron levels so that iron not used for metabolic purposes is 
released from the cells. Iron-export mediated by ferroportin is a permanently active mechanism, 
which ensures iron-homeostasis inside the neuron. Iron is thought to undergo axonal and dendritic 
transport, and as ferroportin is found in the somata, axons, and dendrites of neurons, it probably 
plays an important role to regulate iron levels everywhere in the neuron102. Neurons of some 
forebrain nuclei, however, also contain ferritin, showing that neurons are capable of storing iron117. 
As for iron efflux from brain cells, the detection of Ferroportin 1 (FP1) in most rat brain regions and 
cells, including the endothelial cells of the blood–brain barrier, neurons, oligodendrocytes, 
astrocytes, the choroid plexus as well as ependymal cells of the normal and IRP knockout mice 
101;118;119 implies that this protein may be involved in brain iron efflux, in accordance to the role of 
this protein in iron efflux from enterocytes. A role for Hephaestin (Hp) in iron efflux from brain 
cells has also been hypothesized, but further data are needed to support this hypothesis. 
Increasing amount of data suggest that ceruloplasmin (CP) might also be involved in iron 
release from the brain cells120-122 in particular from astrocytes, which do not contain ferroportin123. 
However, the possibility that CP might play a role not only in iron efflux from, but also iron influx 
into the brain cells via its ferroxidase activity has been also suggested124. It has been suggested that 
the physiological function of CP is provided by its ferroxidase activity. This activity plays a role in 
both iron efflux and iron influx125, but it is highly likely that the major role of CP in brain cellular 
iron balance might be ‘‘uptake’’, and ‘‘release’’ plays a minor role. Recently, interest has been 
focused on the potential role of Heme oxygenase-1 (HO-1), which has been linked to the efflux of 
iron from cells for cellular protection under stress. HO-1 expression in the normal brain is confined 
to a small group of scattered neurons and neuroglia126. There is preliminary evidence that HO-1 has 
a dual role in iron metabolism: it can offer neuroprotection by facilitating the cellular iron export in 
some stress conditions but exert a neuroendangering effect by promoting iron deposition in 
mitochondria in other circumstances88. 
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1.2.2.4 Iron localization in the brain 
Regional level 
Iron can be detected in the ex vivo brain using chemical methods and histochemistry and in 
vivo using magnetic resonance imaging (MRI)127.  
Iron is present in the brain as heme iron and non heme iron128. Heme containing proteins include the 
mitochondrial electron transport cytochromes (b, c1, c, a, a3). Non heme proteins,  in addition to the 
storage pool of nonheme iron as ferritin, include a large number of enzymes in various subcellular 
compartments that contain iron not associated with the protoporphyrin ring. Some of these nonheme 
enzymes include mitochondrial ac-glycerophosphate dehydrogenase, aldehyde oxidase, succinate 
dehydrogenase, and various other Fe-S centers in the electron transport system. Other examples 
include xanthine oxidase, tyrosine 3-hydroxylase, tryptophan hydroxylase, and ribonucleoside 
diphosphate128. According to Worm-Petersen, only about 10% of the iron content of the brain is in 
hemoglobin129.  
The study of non heme iron in the brain was made possible by the histochemical 
ferrocyanide-Prussian blue reaction, eponymically referred to as “Perls’ stain.” (The Perls’ stain 
was introduced in 1867 by the Hungarian pathologist, Dr M. Perls)130;131. The Perls’ stain is based 
on detection of ferric ferrocyanide (Prussian blue), which is formed when ferric ions released by 
hydrochloric acid react with potassium ferrocyanide130. The distinction of ‘‘heme-’’ and ‘‘non-
heme-’’ iron in the brain must be attributed to Zaleski (cited by 131) who observed that the iron in 
hemoglobin did not react with potassium ferrocyanide, hence the blue colour had to arise from non-
heme iron. Guizzetti and Spatz (cited by 131) used immersion of fresh or fixed animal and human 
brain slices in Perls’ solution to visualize iron in various gray and white matter structures of the 
brain and theirs are the two most classically cited articles on brain iron localization. In particular, 
the long paper by Spatz offered the first colour illustrations of the unusual differential distribution 
of iron. Spatz found that globus pallidus and substantia nigra gave the most intense iron reaction, 
followed by red nucleus, putamen, caudate nucleus, dentate nucleus and the subthalamic body. The 
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cerebral and the cerebellar cortex, the anterior nucleus of the thalamus, the mamillay body, and the 
central grey matter of the third ventricle gave only a variable and weaker reaction. The reaction was 
less intense in the thalamus but was still stronger than in the cerebral cortex and the subcortical 
white matter. Further histochemical studies have in general confirmed that most of the iron is found 
in the exatra-piramidal structures (e.g.: 129;132-137) with the globus pallidus, substantia nigra, zona 
reticulata, red nucleus and myelinated fibres of the putamen showing the highest iron concentration, 
followed by the striatum, thalamus, cortex and deep white matter, substantia nigra zona compacta, 
and cerebellar cortex. The brain-stem and spinal cord generally showed low iron concentration. 
However, Perls (for Fe3+) and other histochemical techniques, such as Turnbull’s (to detect Fe2+), 
although inexpensive and available, remain relatively insensitive, even with diaminobenzidine 
intensification. Therefore, some researchers130 have subsequently proposed other approaches to 
quantify brain, such as X-ray Energy Spectrometry, Proton-induced x-ray emission (PIXE), 
secondary ion mass spectrometry (SIMS), and Laser microprobe technology, which, however, have 
been scarcely used to quantify iron in normal brain. 
In the last decade, MRI has provided a useful estimation of brain iron. MRI studies have confirmed 
that most of brain iron is found in exatra-piramidal structures.  
Importantly, both histochemical techniques and MRI have also show, in  post-mortem and in 
vivo studies respectively, that in normal individuals, iron levels increase with age in subcortical and 
some cortical gray matter regions138-143. However, the rates of iron accumulation are different in 
various brain structures140. The following graphs, from Hallgren and Sourander seminal work140, 
illustrate the rates of brain iron accumulation during the life span.   
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Fig. 6. Non heme iron in sensory cortex (from Hallgren and Sourander, J Neurochem, 1958140) 
 
 
Fig. 7. Non heme iron in the medulla oblongata (from Hallgren and Sourander, J Neurochem, 
1958140) 
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Fig. 8. Non heme iron in the thalamus (from Hallgren and Sourander, J Neurochem, 1958140) 
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Fig. 9. Non heme iron in the globus pallidus (dotted lines denote standard estimates) (from Hallgren 
and Sourander, J Neurochem, 1958140) 
 
 
Fig. 10. Non heme iron in the putamen (from Hallgren and Sourander, J Neurochem, 1958140) 
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Fig. 11. Non heme iron in the motor cortex (from Hallgren and Sourander, J Neurochem, 1958140) 
 
 
Fig. 12. Non heme iron in the prefrontal cortex (from Hallgren and Sourander, J Neurochem, 
1958140) 
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The globus pallidus has a rich supply of iron during the first two decades and no further 
increase seems to occur after 30 years of age. Although the iron values in the red nucleus and 
substantia nigra show considerable scattering, a rapid increase in iron content during the first two 
decades is also clearly demonstrated. In other structures, such as the putamen, iron deposits increase 
more slowly, and iron concentrations reach maximal values at about the sixth decade. 
Very little is known about gender differences in brain iron. Recently, Bartzokis et al.144 first 
reported that women had lower brain iron levels than men in the caudate, thalamus, and frontal 
white matter. The only available MRI study to assess hemispheric differences in iron content 
showed that the left hemisphere had higher iron deposition than the right in the putamen, globus 
pallidus, substantia nigra, thalamus and frontal white matter145.  
Importantly, it has been pointed out that the non heme iron in the different parts of the brain 
seems to be largely independent of the amounts of storage iron in the iron depots. For example, 
Hallgren et al. failed to find any significant correlation when they plotted non heme brain iron 
levels against iron levels in the liver140.  
Cellular level 
In 1966, Perl’s reaction was modified to enhance visualization of the reaction product with 
3,3 diaminobenzidine(DAB) 146. This modification was a major advancement in the ability to detect 
iron and made study of cellular iron distribution in the animal brain possible.  
Using DAB intensification, an iron staining reaction product is seen predominantly within 
oligodendrocytes but is not generally appreciated within neurons147;148. However, in rat brain, 
positive DAB-intensified iron staining has been reported within neuronal perikarya in the islands of 
Calleja, the dentate nucleus of the hippocampus, the lateral septal nucleus, and the central 
amygdale147;149. Considering the lack of specificity of the stain and the extreme limitations of its 
ability to detect iron except in massive deposition, the negative findings with respect to 
intraneuronal staining are difficult to interpret. It has also been pointed out that with age there is an 
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increase in stainable iron in neurons without a concomitant increase in neuronal ferritin 
immunostaining, suggesting a ferritin independent accumulation of neuronal iron with age.150 
Although predominant in the white matter, iron-positive oligodendrocytes are found 
throughout the brain including in the iron-rich brain nuclei, such as the substantia nigra and 
striatum127;150. 
Intracellularly, iron in oligodendrocytes is found in the perikaryal cytoplasm and 
processes150;151. 
The distribution of iron-positive oligodendrocytes in the white matter tracts is not uniform. 
The white matter tracts that stain with iron have a patchy appearance resulting from areas of robust 
cell staining that extends into processes in the neuropil admixed with areas of no detectable iron 
staining despite the presence of cells152.  
The distribution of iron in olygodendrocytes changes according to developmental phases.  In 
rats models, during normal development, iron first appears in microglia in myelinogenic foci in 
white matter153. As development proceeds, iron appears in oligodendrocytes and is no longer 
detectable in microglia. The appearance of iron (and the iron storage protein ferritin) in 
oligodendrocytes corresponds spatially and temporally to the appearance of myelin. The appearance 
of transferring receptors on oligodendrocytes during development in the optic nerve is clearly 
associated with cells near blood vessels154, supporting the hypothesis that iron accumulation by 
oligodendrocytes and myelin production are biologically linked. 
In addition to oligodendrocytes, microglia are the cell type most often seen to accumulate 
stainable quantities of iron in the brain. 
Ferritin and iron have also been detected in tanycytes and transferrin has been found in the 
choroid plexus and ependima surrounding the third ventricle, suggesting that a transport system 
may exist for the transfer of iron between the brain and cerebrospinal fluid150. 
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1.2.2.5 Iron transport out the brain 
The quantity of iron in the brain increases with age but not as rapidly as would be expected 
from measurement of the rate of iron uptake from the blood at the different ages. Hence some iron 
must be exported91. 
Knowledge about how iron leaves the brain is far from complete. Tf-Fe readily exits the 
brain via the venous system and returns to the systemic circulation through the arachnoid 
granulations 99;138. 
Endothelial cells of the BBB also have a potential capacity to mediate the export of 
elemental iron from brain interstitium to the systemic circulation, although there is no evidence so 
far for direct export of iron from the brain 155.  
Within the CSF transferrin is fully saturated with iron94;156. Nevertheless, the concentration 
of transferrin in CSF is very low so that the capacity to export iron by this route is limited. The CSF 
also contains lactoferrin, ferritin and non-protein-bound iron116;139, which represent additional 
means of iron export from the brain. 
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1.2.2.6 Iron and neurotransmitters 
The effects of iron deficiency on neurotransmitters have been mainly studied by means of 
rat and, more recently, monkey models157. The first rodent studies induced ID predominantly at 
weaning157;158,  at a time period roughly corresponding to the last part of the brain growth spurt in 
the human. More recent rodent models have emphasized the maternal-fetal unit and the role of 
maternal ID in determining postnatal iron status in the offspring. One such model induces ID during 
fetal life and continues an ID diet during lactation until weaning at around postnatal day (P) 21142. 
This gestational/lactational model is designed to mimic the common worldwide human condition 
where mothers are ID during pregnancy and breastfeed their infants for 1 to 2 years, with 
widespread ID in this age period. Another model focuses on fetal and neonatal ID. ID diet is used as 
in the gestational/lactational model through about P7, with an iron-sufficient diet thereafter (P10 is 
considered to be the rodent “brain equivalent” of term human birth). The purpose of this model is to 
mimic human conditions such as intrauterine growth restriction (IUGR) or gestational diabetes 
mellitus where the fetus is ID during gestation but then receives adequate dietary iron after birth157.  
Given that the rate-limiting enzymes for the synthesis (tyrosine and tryptophan hydroxylases) and 
catabolizing enzymes (monoamine oxidase) of the aminergic neurotransmitters (dopamine, 
serotonin, and noradrenaline) were shown to be dependent on iron for their full enzymatic activity, 
it was hypothesized that iron is involved in the metabolism of monoamine neurotransmitters and 
that iron deficiency leads to alterations in the production and functioning of these 
neurotransmitters159. Moreover, it has been reported that iron is co-localized with dopaminergic 
neurons throughout the brain159;160. 
In part contrary to this hypothesis, Youdim and colleagues demonstrated that, whereas iron 
deficiency induced in rats by feeding them a diet low in iron resulted in the reduction of iron-
dependent enzymes (monoamine oxidase, phenylalanine hydroxylase, succinic dehydrogenase, 
cytochrome oxidase to mention a few) in peripheral tissues, none of the brain enzymes containing 
iron (including tyrosine hydroxylase, tryptophan hydroxylase hydroxylase, and monoamine 
 74 
oxidase) as a cofactor was changed161;162 (Table 6 ) despite the fact that adult (48 days old) rat brain 
iron was reduced by 30% to 40% in the striatum, hippocampus, cortex, and raphe nucleus (Table 6). 
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Tab. 6. Effects of iron deficiency on  brain iron enzymes (from Youdim, Nutrition, 2000159). 
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Moreover, Youdim et al. also reported unaltered brain (striatum, caudate nucleus, and raphe 
nucleus) levels and turnover of dopamine, noradrenaline, and serotonin162 (Table 7). 
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Tab. 7. Neurotransmitters and their precursor levels in brains of iron-deficient rats (from Youdim, 
Nutrition, 2000159). 
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However, the same group162 interestingly reported an alteration in the dopamine receptors: 
by employing radioligand analysis of dopamine D1 and D2 receptors, they observed an increase in 
Ka of dopamine D1 and a decrease of dopamine D2 Bmax in the striatum of iron deficient rats. 
Interestingly, this effect was related to iron deficiency and not to the anemia resulting from it 
because haemolytic anemia induced by chronic treatment of rats with phenylhydrazine does not 
alter brain dopamine D2 receptor number or their behavioral responses146;147. Alterations in D1 and 
D2 receptors have also been replicated by other authors163;164. In line with these observations, 
Nelson et al. reported that the response to dopamine reuptake blockade was significantly attenuated 
in iron deficient rats compared with control165. 
Tab. 8 summarizes the biochemical consequences of reduced dopamine D2 receptor in the 
brains of iron-deficient rats. 
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Tab. 8. Biochemical and behavioral consequences of reduced dopamine d2 receptor in the brains of 
iron-deficient rats (from Youdim, Nutrition, 2000159). 
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In the brain regions where iron does not fall, there are no changes in DA receptors166.  
However, further studies have reported an alteration of neurotransmitters themselves. It has been 
reported that the effects of early iron deficiency on brain iron and neurotransmitters depend on 
when they are assessed and on the severity of the iron deficiency167. For instance, modest iron 
deficiency during gestation does not lead to marked changes in rat pup brain iron content until the 
latter part of lactation151. There are, however, elevations in striatal dopamine transporters, D2R, and 
catecholamines that precede measurable changes in regional iron. By weaning, both brain iron and 
catecholamines are reduced to levels 20% to 30% below controls, suggesting that earlier elevations 
are an “adaptive” response to iron deficiency. Others have interpreted the elevations in the levels of 
cathecolamines as the expression of a defect of their uptake and catabolism168. In line with this 
hypothesis, Mackler et al. have reported decreased activity of aldehyde oxidase and consequent 
increased levels of serotonin in brain of iron deficient rats169. Some of these neurotransmitter 
alterations may relate to the recently observed effects of early iron deficiency on the neuronal 
surface protein Thy1, which is iron responsive. In the dietary iron-deficiency model, Thy1 was 
decreased in the brains of iron-deficient rats170. Thy1 deficiency may affect the release of 
neurotransmitters and the synaptic efficacy and could contribute to a variety of abnormal neuron-
neuron communications in the iron-deficient rat. 
Further research also showed that iron deficiency resulted in a reduction of dopamine 
transporter in striatum171 or in the nucleus accumbens and prefrontal cortex163. Erikson et al. have 
suggested that that elevated levels of extracellular dopamine reported in some studies assessing 
extracellular levels of dopamine in iron deficient rats in the striatum of iron-deficient rats are likely 
to be the result of decreased DAT functioning and not increased rates of release. Moreover, it has 
been reported that the impact of iron deficiency on dopamine transporter is more pronounced in 
males than females172.  
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Moreover, experiments with pheochromocytoma (PC12) cells and neuroblastoma cells 
demonstrated a dose response relationship between iron chelation and expression of the DA 
transporter160. 
The mechanism by which ID brings about the reduction of dopamine D2 receptor number 
and thus dopamine neurotransmission in rat brains is not fully understood. It has been hypothesized 
that iron could be part of the dopamine-receptor site to which agonists (apomorphine) and 
antagonists (phenothiazines) bind159. 
Although most of the research activity on brain iron and neurotransmitters has focused on 
DA, there is evidence that both serotonin and norepinephrine (NE) metabolism are also altered in 
brain iron insufficiency. The serotonin transporter density was significantly lower in brains of iron-
deficient173 mice whereas in vivo micro dialysis in rats provided evidence for decreased rates of 
uptake of NE168. Studies by Beard and co-workers showed that iron deficient anemic women and 
rats had elevated plasma NE levels 174.  
Recent studies have also showed that the serotonin transporter and norepinephrine 
transporter densities are altered by dietary iron deficiency 175 176 177 178;178.  
As for other neurotransmitters, Youdim et al. have also reported a reduction of GABA 
receptors in iron deficient rodents179, confirming the observations by Li180, Taneja et al.181,  and 
Shukla et al.182 that iron deficiency in the brain could change the utilization and metabolism of 
GABA. 
Interesting, brain-iron distribution is related to the distribution of GABA systems. The high-
iron regions of the brain receive GABAergic input, and inhibition of GABA degradation reduces 
brain iron.  
The group by Youdim also noted interesting dopamine opiate interactions in iron deficient 
rodents179. The brain regions known to contain the highest concentrations of iron (globus pallidus, 
substantia nigra, caudate nucleus, and putamen) are also enriched with the densest population of 
opiate-peptide (enkephalins, endorphins, and dynorphin B) neurons. During the past few years it has 
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become evident that endogenous opiopeptides are involved in memory and learning179 because 
central injection of such peptides cause amnesia and forgetfulness. Consistent with this finding is 
that administration of naloxone (opiate antagonist) improves memory179. Indeed, ID rats show a 
highly significant increase in opiate-analgesic response which can be blocked by naloxone183. The 
increase of analgesic response in ID rats has been attributed to the highly significant elevation of the 
opiate peptides (dynorphin Band met- and leu-enkephalin) as measured in the globus pallidus, 
substantia nigra, caudate nucleus, and central grey by radioimmunoassay. The mechanism of 
increased opiopeptides and their action in ID animals are not fully understood. However, a link with 
the diminished central dopaminergic neurotransmission, as seen in ID rats, has been postulated 
because dopamine is inhibitory to opiates183;184  
The evidence for alterations in dopamine or norepinephrine in humans is limited. Voorhess 
et al185 showed that urine of iron-deficient infants was particularly high in norepinephrine and 
returned to normal with the restoration of iron adequacy. Webb et al.186 also found high levels of 
norepinephrine in iron deficient children and suggested that this is linked to decrease activity of 
monoaminoxidase. Beard et al. (18) showed alterations in plasma norepinephrine levels in iron-
deficient women during cold stress174.  
 
 
 
 
 
 
 
 
 
 
 83 
1.2.2.7 Iron and myelination 
Oligodendrocytes are the glial cells in the CNS that produce myelin. Oligodendrocytes stain 
for iron more robustly that any other cell in the normal adult brain150;151. The highest period of iron 
uptake in the CNS coincides with the peak myelination151;187. There is evidence that iron deficiency 
leads to reduced myelination188. The iron acquisition by oligodendrocytes at the peak of myelination 
is likely linked to their energy metabolism. Many of the enzymes involved in ATP production, 
cholesterol and fatty acid synthesis, which are precursors of myelin, are iron dependent. These 
include HMG-CoA reductase, succinic dehydrogenase, NADH dehydrogenase, dioxygenase and 
glucose-6-phosphate dehydrogenase, and most of these are enriched in oligodendrocytes compared 
to other cells in CNS189. Beard and colleagues have reported that both CNPase activity and 
concentration (marker of oligodendrocytes metabolic activity) and myelin basic protein (MBP) 
concentration were reduced in iron deficient rats 160. Moreover, Wu et al. have reported lower 
density of 2-,3-cyclic nucleotide 3-phosphohydrolase (CNPase, marker of oligodendrocyte) in iron 
deficient rats190. Interestingly, a single apo-transferrin intraparenchymal injection administered to 
myelin deficient rat pups enabled mutant oligodendrocytes to synthesize myelin basic protein and to 
myelinated axons, indicating that transferrin availability is essential for oligodendrocyte maturation 
and function191. Iron deficiency effects on myelin production suggest that iron requirements for 
myelin are related to metabolic processes underlying general myelin production rather than limited 
to lipid or protein biosynthesis. 
Several studies have shown that apoTf acts on pro-oligodendrocytes inducing their rapid 
differentiation from glial precursor cells192;193. It has been pointed out that iron may affect 
oligodendrocyte development at stages during early embryogenesis rather than during later 
development. 
Emerging data suggest that adequate iron in the brain, at least at some point during the 
intervention, are required for the full apoTf effect. It appears that there is a ‘‘critical temporal 
window’’ in the mouse brain development in which oligodendrocytes are responsive to 
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apotransferrin. Rats models show that when oligodendrocytes reach maturation their complete 
downregulation of transferrin receptor makes them no longer responsive to exogenous transferrin114. 
Despite their lack of transferrin receptor, mature oligodendrocytes continue to remain the principal 
cell in the brain that stains for iron. Presumably there is a continued need for iron uptake given that 
iron deficiency in the adult can lead to loss of myelin194. Therefore, uptake of iron into 
oligodendrocytes may continue in the absence of transferring195. Preliminary data suggest that H-
ferritin may act as iron delivery protein for oligodendrocytes115. Connor and co-workers suggested 
that two alternative iron delivery mechanisms exist in the adult brain: transferrin in grey matter and 
neurons, and ferritin in white matter and oligodendrocytes, while in the perinatal period, the main 
source of iron for oligodendrocytes would be still transferrin, given the reported spatial and 
temporal association between myelinogenesis and trasferrin154;196;197. The advantage of a separate 
iron delivery for oligodendrocytes in form of H-ferritin may be avoiding competition for 
transferrin- bound iron with the neurons and other brain cells that primarily use transferrin system 
while still preserving iron supply to oligodendrocytes in form of H-ferritin. 
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1.2.2.8 Iron and neuronal metabolism 
Iron is an essential component of cytochromes a, b, c, cytochrome oxidase, and the iron 
sulphur complexes of the oxidative chain127. 
Dallman198 demonstrated that iron deficiency had primary effects in the brain tissue, 
independently of anaemia, by documenting reductions in brain cytochrome c concentrations. He 
proposed that reduced brain tissue iron concentrations altered cerebral energy metabolism through 
loss of cytochromes and inefficient ATP generation and electron transport. These findings are 
supported by regionally distributed losses of cytochrome c oxidase, a marker of neuronal energy 
status, particularly in the hippocampus and frontal cortex199. Hippocampal and striatal abnormalities 
in energy metabolism, as assessed by sequential magnetic resonance spectroscopy studies of live 
rodents, indicate acute (while iron-deficient) and persistent (during iron repletion) changes200;201. 
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1.2.2.9 Iron and neuronal structure 
In iron deficient rats, significant delays and abnormalities in the structural development of 
the dendrites of CA1 area neurons are found, as assessed by MAP2 (microtubule-associated protein 
2) expression202. This protein, which is important for dendritic scaffolding, may be affected 
secondarily by lack of adequate energy to support complex dendritic growth or by a direct effect on 
MAP2 gene expression203. Accompanying this altered structure were magnetic resonance 
spectroscopy findings consistent with intracellular sequestration of the neurotransmitter 
glutamate201, reduced concentrations of the activity-dependent signalling molecule CaMKIIα 
(Ca2+/calmodulin-dependent protein kinase IIα), and reduced transcript and protein concentrations 
of an important post-synaptic density protein, PSD-95. 
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1.2.2.10 Iron and genes expression 
Although the above mentioned effects of iron deficiency may well be due to the lack of 
post-translational incorporation of iron into functional haemoproteins and iron–sulfur proteins, two 
recent studies have defined the effects of early iron deficiency on gene expression of proteins 
involved in myelination, dendritic morphology, the neurometabolome and cellular energetics in the 
whole brain203 and in the hippocampus204. For example, in the hippocampus, 250 known gene 
transcripts were identified by microarray to be altered by iron deficiency at P15; 30% were involved 
in primary metabolism, 20% in signal transduction, and 11% in establishment of localization204. 
Specific genes and proteins critical for hippocampal neuron differentiation and plasticity 
were involved [40]. The transcripts for BDNF (brain-derived neurotrophic factor) III and IV, as 
well as the transcript and protein levels of its receptor, are downregulated throughout the period of 
iron deficiency205. 
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1.2.2.11 Consequences of iron deficiency on behavior and cognitive functions 
A large body of research is available on the relationship between iron deficiency (with, and, 
to less extent, without anemia) and behavior cognition, both in human and in animal models. Since 
it is not possible to cite here all the published papers on this topic, we refer to the two most 
comprehensive and recent systematic reviews and to the most relevant papers cited by these 
reviews167;206. 
Studies examining alterations in behavior or cognition during or soon after the period of 
iron deficiency 
In almost all case-control studies (for a review, see:207;208) comparing otherwise healthy full-
term infants with iron deficiency anemia to infants with better iron status, their mental development 
test scores averaged 6 to 15 points lower. One preventive trial209 has showed the positive effects of 
iron supplementation on global mental functioning. Among case-control studies that included an 
assessment of motor development, most found that infants with iron-deficiency anemia received 
lower motor test scores, averaging 6 to 17 points lower167. Among five preventive trials with well-
nourished term infants, three showed motor benefits of iron supplementation209-211. 
Every case-controlled study that examined social-emotional behavior found differences in iron-
deficient anemic infants (e.g., more wary, hesitant, solemn, unhappy, kept closer to their 
mothers)167. Two of three randomized trials to prevent iron deficiency that assessed this domain 
reported social-emotional differences as well209;212. One preventive trial did not find social-
emotional effects211. 
Many of the case-controlled studies have included assessments before and immediately after 
iron therapy. Most studies report that differences in behavior and development persist in the 
majority of iron-deficient anemic infants even after a full course of iron treatment (2–6 months, 
depending on the study)209. However, three studies reported improvements, sometimes dramatic, in 
mental and/or motor test scores after iron therapy213. 
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Two studies related perinatal iron deficiency to newborn temperament-like behaviors. One 
reported higher levels of irritability in infants whose mothers were iron deficient214. In the other215, 
lower levels of neonatal Hb and serum iron (and ferritin to a lesser degree) were correlated with 
higher levels of negative emotionality and lower levels of alertness and soothability. A small 
randomized, controlled trial involving breast-fed infants in Canada showed a benefit of early 
(between 1 and 6 months of age) iron supplementation on motor development and visual acuity at 
12 months210. 
Long-Lasting Effects of Iron deficiency Beyond Infancy: Global Outcomes 
These studies, most of which have been conducted at late preschool or early school age, 
followed children who had anemia (presumably due to iron deficiency), iron-deficiency anemia, or 
other indications of chronic severe iron deficiency in infancy. 
There are at least six follow-up studies at late preschool age. In general, most of these 
studies reported a significant correlation between iron deficiency anemia and global IQ or 
equivalent measures of global outcome167. 
Only one study has related a direct measure of iron status at birth (cord ferritin 
concentration) to development years later. In this sample of 278 US children, those with cord 
ferritin concentrations in the lowest quartile received lower scores for language ability, fine-motor 
skills, and tractability at 5 years216. 
There are at least four reports of outcome in school-aged children167. All found significant 
lower learning in formerly anemic children.   
There is only one follow-up study past 10 years of age217. Children who had been treated for 
severe, chronic iron deficiency in infancy still tested lower in arithmetic and writing achievement 
and motor function compared with 114 children with good iron status in infancy before and/or after 
treatment. Affective and social/emotional differences were still observed. The parents and teachers 
of formerly iron deficient children rated their behavior as more problematic in several areas, 
agreeing in increased concerns about anxiety/depression, social problems, and attention problems. 
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Neurocognitive and Neurophysiologic Outcomes 
Two prospective studies, conducted respectively in Chile and Costa Rica167, have assessed 
neurocognitive and neurophysiologic outcomes in formerly anemic children. In both Chile and 
Costa Rica, children with iron deficiency anemia or some other indication of chronic, severe iron 
deficiency in infancy had poorer performance on tests of some specific cognitive functions. For the 
Costa Rica sample at 11 to 14 years, poorer performance was observed for tachistoscopic threshold, 
spatial memory, and selective attention. At 5 and 10 years in the Chile follow-up and 19 years in the 
Costa Rica follow-up, formerly iron-deficient children did worse on executive function tasks, 
particularly ones that require inhibition and planning. 
Of note, iron deficiency typically occurs in disadvantaged environments, but the findings 
from most of the above mentioned studies have been statistically significant after controlling for 
background factors in a wide variety of different settings. Nonetheless, the confluence of iron 
deficiency with a disadvantaged environment means that causal inferences cannot be made with 
confidence from case-controlled, long-term follow-up studies. 
However, a note of caution has been expressed in a systematic review by McCann and 
Ames206. After reviewing the methodology of the above mentioned studies, they concluded that, 
although most of the 5 conditions of causality (association, plausible biological mechanisms, dose 
response, ability to manipulate the effect, and specificity of cause and effect) are partially satisfied 
in humans, animals, or both, a causal connection between iron deficiency and alteration in 
behavior/cognition has not been clearly established. Moreover, the same authors pointed out that 
most of the available studies included children with iron deficiency plus anemia. According to 
McCann and Ames the question if iron deficiency without anemia leads to cognitive and 
behavioural dysfunctions is still unsolved. In rats, anemia per se does not result in biochemical 
brain effects associated with iron deficiency anemia206;218. However, it cannot be excluded that the 
poor performance of iron deficient children (or animals) without anemia on cognitive or behavioral 
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tests is confounded by generalized effects of anemia on physical energy levels as opposed to 
specific effects of iron deficiency in the brain. 
However, despite an unfortunately small number of studies involving iron deficiency 
without anemia, some evidence, both direct and indirect, does suggest that cognitive or behavioural 
performance and brain function could be affected, particularly if deficiency occurs during critical 
stages of development.  
Effects on cognitive, behavioral, or motor activity in rodents and monkeys 
 
Animal studies provide important corroborative evidence and other information that is 
difficult or impossible to obtain in human studies. For example, some types of experiments cannot 
be done in humans, such as mechanistic studies that correlate changes in biochemical indicators of 
brain function to performance deficits on cognitive or behavioral tests. Also, much greater 
flexibility of design is possible in animal experiments, which avoids some serious confounders in 
human studies206. In rodents model of iron deficiency, motor or exploratory activity was most 
frequently measured, using activity monitors, the hole board, or home orientation and open-field 
tests. However, some methods target cognitive functions, such as learning and memory, more 
directly, such as the Morris water maze and passive or active avoidance tests.  
Twenty rodent and 2 monkey studies that examined cognitive, behavioral, or motor activity 
in iron-restricted animals were identified in the review by McCann and Ames206. Regardless of the 
degree to which animals were iron-restricted, regardless of whether they were iron deficient with or 
without anemia at the time of testing and regardless of the degree of undernutrition or whether it 
was controlled for, changes in activity or behavior compared with that in controls were reported on 
at least some tests in all studies. Dietary intake of iron was restricted either during gestation or 
before weaning or after weaning. In all cases, statistically significant performance differences 
between iron restricted and control groups on at least some performance tests were reported. 
Some long-term behavioral alterations in the developmental rat model of early deficiency 
closely parallel prior experimental studies of specific early dopaminergic insults (perseveration, 
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behavioural inflexibility, increased anxiety, lifelong hyperreactivity to novel objects and 
experiences in an unfamiliar environment, but normal responses to the same stimuli in the home 
cage). Thus, rats models show that early iron deficiency is associated with impairment in attentional 
and affective responses. Specific perinatal damage to nigrostriatal dopamine neurons or intrinsic 
striatal or corticostriatal neurons, whether induced by early iron deficiency or pharmacologic injury, 
results in fine motor, gross motor, motor sequencing, and sensory deficits in rats. These data further 
support the hypothesis that iron deficiency in infancy leads to a chronic disorder of dopaminergic 
and corticostriatal function217. 
Important differences exist between animals and humans that must be taken into account in 
evaluating the implications of results for humans. For example, in rats and mice, offspring are born 
at an earlier stage of development than are humans, with the period of the brain growth spurt 
generally considered to begin at birth and extend up to weaning (usually postnatal day 21). In 
humans, the brain growth spurt begins in the last trimester of pregnancy and extends through the 
first 2 y of life. Another important difference between rodents and humans is that rats have a greater 
requirement for dietary iron during development than do humans because the rate of development is 
relatively much more rapid. Also, in the great majority of the studies discussed below, the dietary 
supply of iron was much more severely restricted than in human studies. Thus, species and 
dosimetry differences must be considered when results in animals are extrapolated to humans206. 
 
Neurophysiologic alterations 
Evidence on neurophysiologic effects of iron deficiency in children is limited but growing. 
One study219 has compared auditory brainstem response (ABR) and visual evoked potentials (VEP) 
in formerly iron deficient anemic children and controls. The formerly iron-deficient anemic group 
(n = 41) showed longer ABR and VEP latencies compared with children who had been non-anemic 
in infancy (n = 43). The magnitude of effects was large: 1 to 1.2 SD.  Another study (cited in 167) 
has evaluated polysomnographic recordings during an overnight sleep study for 27 formerly iron-
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deficient anemic children and 28 children who had been non-anemic in infancy. There were 
significative differences in measures of the sleep/wake cycle, including REM latency, duration of 
REM episodes and their pattern through the night, the duration of slow-wave sleep episodes early in 
the night, both the isolated REMS and non-isolated REMS indices, and inter-REM intervals. It has 
also been reported an overall increase in intra-individual variability of spontaneous activity, 
measured with actigraphy, in formerly iron-deficient anemic children, especially for the duration of 
different states during both day and night175. 
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1.2.2.12 Estimation of brain iron by means of MRI 
 
Physical principles of relaxometry (The contents and figures of this section are taken from: Westbrook, Roth, 
Talbot. MRI in practice. Blackwell Publishing. 2005 220, chapters 1 and 2) 
  
All things are made of atoms, including the human body. The most abundant atom in the 
body is hydrogen. The atom consists of a central nucleus (subdivided into protons and neutrons) 
and orbiting electrons. Three types of motion are present within the atoms: 1. Electrons spinning on 
their own axis; 2. Electrons orbiting the nucleus; 3. The nucleus itself spinning about its own axis. 
(Fig. 13). 
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Fig. 13. The atom and motions present within the atom (from: Westbrook, Roth, Talbot. MRI in 
practice. Blackwell Publishing. 2005 220). 
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The spin of the nucleus derives from the individual spins of protons and neutrons within in 
the nucleus. Pairs of subatomic particles automatically spin in opposite direction. In nuclei that have 
an even mass number, i.e. the number of protons equals the number of neutrons, half spin in one 
direction and half in the other. The nucleus itself has not net spin. In nuclei with odd mass number, 
spin directions are not equal and opposite, so the nucleus itself has a net spin or angular momentum. 
These are know as MR active nuclei. MR active nuclei are characterize by their tendency to align 
their axis of rotation to an applied magnetic field, thus acquiring a magnetic moment (Fig. 14). 
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Fig. 14. The magnetic moment of hydrogen nucleus (from: Westbrook, Roth, Talbot. MRI in 
practice. Blackwell Publishing. 2005 220). 
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The hydrogen nucleus is the MR active nucleus used in clinical MRI. It is used because it is 
very abundant in the human body and because its solitary proton gives it a relatively large magnetic 
moment. In the absence of an applied magnetic field, the magnetic moments of the hydrogen nuclei 
are randomly oriented. When placed in a strong static external magnetic field, termed B0, the 
magnetic moments of the hydrogen nuclei align parallel with the magnetic field. According to 
quantum theory (first described by Max Planck in 1900), hydrogen nuclei possess energy in two 
discrete quantities or populations termed low and high. Low energy nuclei align their magnetic 
moments parallel to the external field (spin up nuclei), while high energy nuclei align in the anti-
parallel direction (spin-down nuclei). As there is a larger number aligned parallel, there is always a 
small excess in this direction that produces a net magnetic moment (NMV) (Fig. 15). 
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Fig. 15. The net magnetization vector  (from: Westbrook, Roth, Talbot. MRI in practice. Blackwell 
Publishing. 2005 220). 
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The influences of  B0 produces an additional spin, called precession, and causes the magnetic 
moments to follow a circular path around B0, called precession. The speed at which the magnetic 
moments wobble around B0 is called precessional frequency, which is proportional to B0. according 
to the equation: ω0: B0 X λ, where ω0 is the precessional frequency, B0 is the magnetic field strength 
of the magnet, and λ is a constant (the gyro-magnetic ratio) (Fig. 16). 
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Fig. 16. Precession of the spin-up and spin-down populations (from: Westbrook, Roth, Talbot. MRI 
in practice. Blackwell Publishing. 2005 220). 
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The application of a radio frequency (RF) pulse causing resonance makes NMV to move out of 
alignment away from B0 (usually the flip angle is 90°, i.e. the NMV moves from the longitudinal to 
the transverse plane) (Fig. 17). 
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Fig. 17. The flip angle (from: Westbrook, Roth, Talbot. MRI in practice. Blackwell Publishing. 2005 
220). 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 104 
The other result of resonance is that the magnetic moments of hydrogen nuclei move into phase 
with each other. The MR signal is produced when coherent (in phase) magnetization cuts across a 
receiver coil (Fig. 18).  
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Fig. 18. Generation of the signal (from: Westbrook, Roth, Talbot. MRI in practice. Blackwell 
Publishing. 2005 220). 
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When the RF pulse is switched off, the NMV is again influenced by B0 and it tries to realign 
with it. This process is called relaxation. Two processes occur: 1. The amount of magnetization in 
the longitudinal plane gradually increases (T1 recovery); 2. At the same time but independently, the 
amount of magnetization in the transverse plane gradually decreases (T2 decay). T1 recovery is 
causing by nuclei giving up their energy to the surrounding environment or lattice. T1 is the time it 
takes 63% of the longitudinal magnetization to recover in the tissue (Fig. 19). 
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Fig. 19. The T1 recovery curve (from: Westbrook, Roth, Talbot. MRI in practice. Blackwell 
Publishing. 2005 220). 
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T2 decay is causing by nuclei exchanging energy with neighbouring nuclei. T2 is time it takes 63% 
of the transverse magnetization to be lost (Fig. 20). T2* decay is faster than T2 and is a combination 
of : T2 decay itself and dephasing due to magnetic field inhomogeneities. 
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Fig. 20. The T2 decay curve (from: Westbrook, Roth, Talbot. MRI in practice. Blackwell 
Publishing. 2005 220). 
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Water and fat have different T1 and T2, as reported in Fig. 21-22 
Fig. 21a. T1 recovery in fat (from: Westbrook, Roth, Talbot. MRI in practice. Blackwell Publishing. 
2005 220). 
 
 
 
Fig. 21b. T1 recovery in water (from: Westbrook, Roth, Talbot. MRI in practice. Blackwell 
Publishing. 2005 220). 
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Fig. 22a. T2 decay in fat (from: Westbrook, Roth, Talbot. MRI in practice. Blackwell Publishing. 
2005 220). 
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Fig. 22b. T2 decay in water (from: Westbrook, Roth, Talbot. MRI in practice. Blackwell Publishing. 
2005 220). 
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 This is useful to image and differentiate them in biological tissues. As the T1 time of fat is 
shorter than that of water, the fat vector (representing magnetic moment) realigns with B0 faster 
than water vector. After a certain time that is shorter than the total relaxation times of the tissues, 
the next RF excitation pulse is applied. The RF excitation pulse flips the longitudinal components 
of magnetization of both fat and water into the transverse plane. As there is more longitudinal 
magnetization in fat before the RF pulse, there is more transverse magnetization in fat after the RF 
pulse. Fat therefore has a high signal and appears bright on a T1 contrast image. As there is less 
longitudinal magnetization in water before the RF pulse, there is less transverse magnetization in 
water after the RF pulse. Water therefore has a low signal and appears dark on a T1 contrast image. 
Such images are called T1 weighted images.  
The T2 time of fat is shorter than that of water, so the transverse component of 
magnetization of fat decays faster. The magnitude of transverse magnetization in water is large. 
Therefore, water has a high signal and appears bright on a T2 contrast image. On the other hand, the 
magnitude of transverse magnetization in fat is small. Fat therefore has a low signal, and appears 
dark on a T2 contrast image. Such images are called T2 weighted images.  
Magnetic properties of iron 
Iron in biologic systems is found with a variety of oxidation states, reduction potentials, 
magnetic properties, degrees of aggregation, solubilities, and mobilities221. Each of these variables 
influences not only biologic activities and toxicities but also the detection and quantification of iron.  
As previously stated, there are two categories of iron in the brain: heme iron, in hemoglobin and 
some enzymes like perioxidases, and nonheme iron. The types of nonheme iron in the brain include 
1. Low-molecular weight complexes; 2. Metalloproteins like transferrin, melanotransferrin and 
lactoferrin; 3. Storage proteins such as ferritin and hemosiderin and 4. Ionic iron. Iron in the form of 
biogenic magnetite has also been reported222. 
At least one third of the nonheme iron in the brain is in the form of ferritin, but 
concentrations can be much greater in iron-rich gray matter222. For example, Dedman et al.223 
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suggested that 85–88% of the nonheme iron in the parietal cortex is located in ferritin. Ferritin and 
hemosiderin are considered to be the only forms of nonheme iron present in sufficient quantities to 
affect MR contrast in the human brain224. As discussed above, transferrin concentrations in brain 
tissue are at least 10 times lower than ferritin and it can only bind two iron atoms compared to 
thousands of iron atoms within each ferritin molecule. The concentrations of other iron species, like 
free iron aqua ions, the labile iron pool, or nontransferrin- bound iron are also considered to be too 
low to affect MR contrast224. The human brain also contains other ions with magnetic properties, 
like copper and manganese. However, Schenck224 suggests logical concentrations of copper and 
manganese are too small to produce detectable MR contrast. 
Ferritin has a large spherical protein coat, about 12 nm in diameter, that surrounds a 
crystalline core of hydrous ferric oxide [5Fe2O3d 9H20]225. There can be up to 4500 iron atoms 
stored in the 8-nm-diameter internal cavity of one ferritin protein. Iron (II) passes into the core 
through six channels in the protein coat and is oxidized to iron (III) for storage. It was at first 
suggested that ferritin has paramagnetic (see Tab. 9 for a definition of “paramagnetic”) properties. 
Aggregates of paramagnetic particles that are largely shielded from the water by a protein shell 
exert their effect on MR relaxation by dephasing the magnetic spins of the protons diffusing in their 
vicinity. This is appropriately called the “outer sphere mechanism”. It results in T2 relaxation time 
reduction and produces hypointense regions on T2-weighted MR images226. On the other hand, 
individual magnetic ions, or small ion clusters, in direct exposure to the solvent water molecules 
have their major effect on T1 via the so-called inner sphere mechanism and reduce T1 to produce 
hyperintense regions in T1-weighted images226.   
As ferritin acts primarily through the outer sphere mechanism, the major effect of brain iron 
on MR images is a reduction in T2 and much reduced effect on T1 relaxation rates224. However, it 
has been pointed out by Bizzi and colleagues227 that relaxation rates attributed to ferritin are 
generally found to be too high to be explained by simple paramagnetism. In fact, the ferrihydrite 
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crystal structure of ferritin is antiferromagnetic and, because of the nanometric size of the grains, 
ferritin is also superparamagnetic.  
One of the properties of small antiferromagnetic crystals is that they saturate (see Tab. 9 for 
the definition of saturation) at much lower magnetic field strengths than paramagnetic substances 
do. In an early report, a theoretical calculation for fully loaded ferritin (4500 iron atoms), according 
to Neel's theory228, predicts that saturation will begin at around 1.0 T at body temperature. 
However, a number of recent studies138;229;230 have reported a strong linear correlation between the 
relaxation rate and the field strength (1.0 T and up) in either ferritin solutions or iron rich brain 
areas. No saturation effect has been observed. The size of the ferritin core may be a factor since the 
field strength needed for saturation depends inversely on crystal size. Thus, only when the iron 
content of the particle is sufficiently high would it lead to magnetic saturation at lower field 
strengths.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 116 
Table 9. Magnetism: Glossary (from Bizzi et al., Radiology, 1990 227). 
________________________________________________________________________________________________  
 
· Paramagnetism. Magnetism found in substances with unpaired electrons, arising mostly 
from the electron spin. Paramagnetic substances include iron, manganese, nickel, cobalt, 
chromium, the rare earths (e.g., gadolinium), and molecular oxygen. In the absence of an 
applied magnetic field, the spins point in random directions, and there is no observable 
magnetism. In the presence of an external field, the individual magnetic moments become 
partially aligned and create an additional reinforcing magnetic field. The degree of 
alignment is proportional to the applied field strength, but at normal MR imaging field 
strengths and temperatures, it is less than 1% of maximum 
 
· Ferromagnetism. A much stronger magnetism created when paramagnetic atoms in a crystal 
lattice become locked into magnetic alignment by interatomic forces. The best known 
example is metallic iron, in which field strengths well over 1T can be found at room 
temperature. 
 
· Antiferromagnetism. A variation of ferromagnetism, found in certain crystals, in which 
interatomic forces create an antiparallel magnetic alignment; that is, neighboring atoms 
point magnetically in opposite directions. In general, the number of paramagnetic atoms 
pointing in each direction is the same, and there is no net magnetization. 
 
· Superparamagnetism. When the crystal size is very small, less than about 10 nm, surface 
effects create an inequality in the two spin populations, and hence a net permanent magnetic 
moment of the crystal. The population inequality is on the order of the square root of the 
number of paramagnetic atoms, so this moment is much smaller than that of a comparably 
sized ferromagnet but still large compared with a single atom. These large crystalline 
moments align with an applied field, as do paramagnetic moments, but, because of their 
strength, the degree of alignment is much greater. Therefore, superparamagnetic materials 
have positive magnetic susceptibilities that are greater than paramagnetic materials and less 
than those of ferromagnetic materials 
 
· Saturation. A condition in which individual magnetic moments, whether paramagnetic 
atoms or superparamagnetic crystals, are completely aligned along the applied magnetic 
field, producing 100% of the possible magnetization. Further increases in applied field 
strength therefore do not increase the magnetization. Saturation is seen in paramagnetic 
substances only at very low temperatures, but superparamagnetic crystals, because of their 
larger magnetic moments, may saturate at room temperature 
________________________________________________________________________________  
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Proposed relaxometry metrics to estimate brain iron  
At present time, there is a lack of consensus on the most desirable MRI method for accurately 
estimating iron content in the brain. Given the magnetic properties of ferritin, the 3 primary 
relaxometry metrics (the transverse relaxation rates or reciprocals of the transverse relaxation times 
(R2 = 1/T2, R2* = 1/T2*, and R2’ = 1/T2’, where R2’= R2*- R2) )have been proposed as pertinent 
to the detection of brain iron231.  
There is considerable debate and controversy as to which MRI technique, if any, most 
closely estimates iron deposition with acceptable sensitivity and specificity231;232. 
R2 
R2 is a transverse relaxation rate measured from a series of spin echoes acquired at different 
echo times and generated with RF refocusing pulses as opposed to gradient reversals.  
Several studies have assessed the usefulness of R2 to estimate brain ferritin levels (e.g.227;229;230;233-
244).   
Both in vitro (e.g.230;244)  and in vivo (e.g.227;233-235;241)  data on healthy subjects show strong 
linear correlations between R2 in gray matter regions and iron concentrations derived from the 
literature140 (as in 233;234;241) or measured directly from the tissue sample (as in 227;235). Schenker et 
al.241 also demonstrate that the correlation between R2 and age in healthy subjects follows the same 
relationship to that of iron and age. Drayer et al.233  pointed out that  iron is the only trace metal in 
the brain that can prominently and preferentially decrease the T2 relaxation time (thus explaining 
the correlation between iron levels and R2) and localize in precisely the topographic basal ganglia 
regions seen on the high field strength MR images. Calcium may increase with age in the globus 
pallidum and dentate nucleus, but it does not accumulate in significant quantities in the red nucleus 
or substantia nigra. The structures that have decreased signal intensity on the T2-weighted images 
have an intensity comparable to cerebral gray matter on non-T2- weighted images. Melanin has 
only a mild effect on Ti relaxivity and a different topographic distribution. Lipofuscin has a similar 
anatomic localization, but will not significantly and specifically affect T2 relaxivity. 
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Although the effect on T2 has been classically attributed to paramagnetic properties of ferritin, 
Bizzi et al.227 noted that the dependence of T2 shortening on field strength was not quadratic, as 
expected for paramagnetic iron, but instead showed a marked levelling off at higher field strengths. 
This magnetic “saturation” is explainable by antiferromagnetism and superparamagnetism of the 
ferritin core and has been observed in ferritin solutions at low temperatures.  This T2 shortening is 
not to be confused with spin-spin paramagnetic relaxation (e.g., from gadopentetate dimeglumine), 
which affects both T1 and T2227. 
Clearly, not all T2 is influenced by ferritin. Schenker et al.241 pointed out that the relaxation 
time in a biological tissue is complex. It can be expressed as a sum of the reciprocal T2 values of 
the different contributing factors: 
 
1                 1                    1 
-------- =  ------        +    ------- 
T2 (tot)     T2 (Fe)         T2 (rest) 
 
where T2 (tot) = measured T2, T2 (Fe) = T2 of iron and T2 (rest) = T2 of all other factors such as 
water, protein, etc.. According to Schenker et al.241,  T2 (rest) seems to be constant and is not 
believed to be responsible for changes of T2 (tot) values under normal conditions. With increasing 
age, however, the T2 (rest) becomes more important due to higher individual variations of the 
tissues, reflecting structural changes in the basal ganglia, on the one hand, and saturation of the iron 
concentration [and therefore constant T2 (Fe)], on the other.  
However, opinions on the correlation between R2 and iron diverge when gray and white 
matter regions are considered together in healthy adults (e.g.245;246) or when certain 
neurodegenerative diseases (HD, PD, AD) are considered  (e.g. 247;248). These discrepancies arise 
because, although R2 is strongly affected by iron concentration, the water content of brain tissue 
also influences R2. On average, there is a 12% difference in water content between white matter 
(roughly 72%), with its high lipid content, and gray matter (roughly 84%)249. The lower water 
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content results in a higher R2 value in white matter tissue compared to gray matter regions with the 
same iron concentration and could explain why some studies (e.g. 245;246;250) did not obtain a strong 
correlation with iron. Moreover, Chen et al.246 pointed out that the relationship between tissue iron 
concentrations and T2 values depends not only on the total amount but also on the physical state, 
form, and microscopic distribution of iron. For example, iron in the arteriolar walls is effectively 
sequestered from free water and may be a less effective relaxation enhancer, accounting, in part, for 
the inconsistency in the observation made between iron-stained brain sections and in vivo MRI 
images. 
To overcome the limitations of R2 in disease, the Bartzokis group adopted the field-
dependent rate increase (FDRI) technique138;139;144;251-255, which measures the difference in R2 of a 
set tissue when applying 2 different field strength instruments by taking into account that R2 is 
higher when measured at a higher magnetic field strength. The difference of the R2 in tissue 
between field strengths correlates well with the quantity of ferritin iron in normal adults and it is 
claimed to be specific for ferritin. Bartzokis and colleagues have shown increased iron levels in the 
basal ganglia of patients with Alzheimer, Parkinson, and other diseases144;252-255, compared with 
healthy controls using FDRI. 
 
R2’ 
Some authors248;256-258 have reported that R2’ (R2*-R2) is more specific for iron than R2, 
since it depends on the susceptibility effect associated with iron and is independent of other 
parameters which affect R2. However, Hikita et al.248;256-259 measured R2’ and R2 in the basal 
ganglia of 13 healthy volunteers and correlated these relaxometric measures with iron content 
derived from historical postmortem data. A linear correlation was identified between R2 and iron 
concentration and between R2’ and iron concentration; but the correlation between MRI and iron 
levels in the gray matter was higher for R2 than R2’. The R2’ measurements were affected by field 
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inhomogeneity related to the skull and thus were less sensitive to interregional differences (e.g., 
iron in the cortex vs. putamen). 
 
R2* 
There has also been some works that found a significant correlation between brain iron and  
R2* 248;256-258;260-264. Interestingly, Zywicke et al.264 have shown that R2* mapping may also be used 
to visualize reduced brain iron, not only brain iron overload. 
Recently, Péran and colleagues260 have published a voxel-based analysis of whole-brain R2* 
maps without defining anatomical structures a priori.  
However, R2* has its own difficulties related to other local background sources of magnetic 
field variation that cause signal loss unrelated to the internal iron content of the tissue265. 
Other MRI metrics used to estimate brain iron levels include: 
 
R1 
Vymazal et al.243 and Ogg and Steen266 have reported that  ferritin does shorten TI, resulting 
in increased signal intensity on Tl-weighted images. It is not clear whether this effect derives 
mainly from isolated iron atoms attached to the protein shell or from the loaded core. 
 
Phase shifts 
Ogg et al.143 and Haacke et al.267  have shown a direct correlation between phase shift and brain 
iron. Phase shift has also been used in a recent study188 to asses age, gender, and hemispheric 
differences in iron deposition in the human brain. 
 
Magnetic field correlation (MFC) 
 
The Jensen group268 proposed this new technique to quantify brain iron. MFC is based on 
the influence of MR signal  by magnetic field inhomogeneities (MFI) (due to spatial variations in 
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magnetic susceptibility). These changes can be due to macroscopic structures such as cavities, 
bones and vessels, microscopic structures such as capillaries, and the presence of paramagnetic 
substances (e.g., metals, contrast agents). MFC imaging is based on a theoretical model of MR 
relaxation in the presence of magnetic field inhomogeneities and uses a non-monoexponential decay 
curve. It differs from R2 and R*2 in having a simpler and more direct connection to MFIs and in 
being, by definition, independent of relaxation mechanisms, such as dipolar interactions, unrelated 
to MFIs. 
 
T2 rho 
A newer relaxometry measure, T2 rho, has been developed which is more sensitive to 
diffusion and exchange of water protons in environments with different local magnetic 
susceptibilities. 
Wheaton et al.269 demonstrated an increase in iron related contrast when comparing images 
created with T2 rho to conventional T2 in the normal human brain. Using a 4T magnet with a 
rotating frame and applying adiabatic pulses. 
Michaeli et al.270 demonstrated a statistically significant shortening of relaxation times in 
substantia nigra tissue in patients with PD compared to normal controls with T2 rho but not with 
routine T2. This correlates with postmortem observations of excessive iron deposition associated 
with the disease and suggests that this novel technique generates better iron related contrast than 
conventional T2 methodology. 
 
Several newer MRI methods for estimating iron content are under investigation. These 
include susceptibility-weighted imaging, magnitude imaging, phase imaging, and advanced analysis 
methods. 
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2. THE STUDY 
2.1 Rationale 
Several lines of evidence, reviewed in detail in the first part of the thesis, suggest that iron 
deficiency might contribute to the etiopathogenesis and pathophysiology of ADHD, at least in a 
subset of patients. 
First, iron is a co-factor of enzymes necessary for the synthesis and catabolism of the 
aminergic neurotransmitters (dopamine, serotonin, and noradrenaline)159, which have been shown to 
be involved in the pathophysiology of ADHD4.  
Second, iron deficiency is associated with a decrease in the dopamine transporter (in 
particular in accumbens and striatum)271, whose gene has been demonstrated to have a significant 
effect in the genetic vulnerability for ADHD16. 
Third, it has been reported that iron deficiency is associated with a dysfunction in the basal 
ganglia179, which are believed to play a significant role in the pathophysiology of ADHD20. 
Fourth, there is a large body of research showing that ID in childhood is associated with 
cognitive and behavioral impairments, including poor attention and hyperactivity167. 
Moreover, two specific and recently developed areas of research further suggest a possible 
link between iron deficiency and ADHD/ADHD symptoms. 
1) The first is the potential association between ADHD and Restless Legs Syndrome (RLS). 
RLS is a sensorimotor disorder characterized by an irresistible urge to move the legs, often 
accompanied by uncomfortable sensations, relieved by movement and worse in the evening or night 
and at rest272. Although clear delineation of dopaminergic pathology in RLS has not yet emerged273, 
several studies, in particular pharmacologic ones, indicate that a dysfunction of dopamine should be 
present in RLS274. Increasing evidence both from peripheral (i.e. serum ferritin levels)275;276 and 
central measures of iron status (i.e. MRI277-280 and autopsy studies281) suggests that iron deficiency 
is a contributing factor to RLS. Although RLS has been traditionally considered a disorder of 
middle to older age, it may occur in children282. As we concluded in a review of published clinical 
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studies283, up to 44% of subjects with ADHD have been found to have RLS or RLS symptoms, and 
up to 26% of subjects with RLS have been found to have ADHD or ADHD symptoms. Given that 
most of the reviewed studies are hampered by methodological issues (lack of representative samples 
and standardized assessment of ADHD as well as of RLS), a definitive conclusion on the nature of 
the relationship between ADHD and RLS symptoms is not possible. We have suggested283;284 that 
several hypotheses may explain the relationship between RLS and ADHD/ADHD symptoms. Sleep 
disruption associated with RLS might lead to inattentiveness, moodiness and paradoxical 
overactivity. Diurnal manifestations of RLS, such as restlessness and inattention, might mimic 
ADHD symptoms. Alternatively, RLS might be co-morbid with “true” ADHD. Subjects with RLS 
and a subset of subjects with ADHD might share a common dopamine dysfunction, caused, at least 
in part, by iron deficiency. 
2) The second is provided by the even more recent interest for the relationship between 
ADHD and obesity/overweight. In a systematic review of empirically based evidence on this issue, 
we concluded that there is a bi-directional link between ADHD and overweight: obese patients 
referred to obesity clinics present with higher than expected prevalence of ADHD (diagnosed 
according to standardized criteria) and subjects with ADHD (both from clinical and population 
based sample) present with significantly higher than the average mean Body Mass Index 
standardized scores. Interestingly, an inverse correlation between iron status and adiposity has been 
reported285. This may be due to the effects of hepcidin, which, as reviewed in the first part of the 
thesis, inhibits enterocyte iron absorption as well as the release of non-heme iron from 
macrophage285.   
Therefore, evidence from different areas of research suggests that iron status should be 
explored in children with ADHD. 
To date, two published studies286;287 from two independent groups have suggested a possible 
role of ID in childhood ADHD. However, both these studies are based on the measure of serum 
ferritin, a peripheral marker of ID. However, how well peripheral iron indices correlate with central 
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(i.e. brain) iron content is still unclear. Although low peripheral iron levels may negatively impact 
on brain iron, several authors failed to find a significant correlation between peripheral and brain 
iron (e.g.: 140). To date, no published study has assessed brain iron levels in children with ADHD by 
means of MRI. 
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2.2 Objectives 
In order to fill the gaps in current literature and advance the field, the aims of the present 
research project are: 
Primary: To compare brain iron levels, estimated by means of MRI, in a sample of children 
with ADHD and in a group of healthy controls. Iron levels were estimated in four regions which 
have been shown to contain iron: thalamus, putamen, pallidum, and caudate. In order to assess if a 
potential central ID is a specific finding in ADHD or it is also present in other psychiatric disorders, 
brain iron levels were also estimated in a group of children with various psychopathologies 
(depressive, anxiety, and psychotic disorders). 
Secondary: To assess the relationship between serum ferritin levels and estimated brain iron 
levels  (in the four above mentioned regions) in children with ADHD as well as in healthy controls. 
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2.3 Methods 
2.3.1 Subjects 
Patients with ADHD, as well as those with other psychiatric disorders, were recruited from 
the outpatient consultation and from the inpatient unit of the Child and Adolescent Psychopathology 
Service of the Hospital Robert Debré in Paris, in the period January 2007-June 2008. Healthy 
controls were recruited from relatives of hospital employees, during the same period. All the 
subjects were recruited by the doctoral candidate during his clinical activity.  
Inclusion criteria were as follows:  
             Children with ADHD: 1. Diagnosis of ADHD according to DSM-IV-TR criteria and 
confirmed by the semi-structured interview Kiddie-SADS-PL; 2. Age range: 6-
14 years. 
             Children with other psychopathologies: 1. Diagnosis of a psychiatric disorder different from 
ADHD according to DSM-IV-TR criteria and confirmed by the semi-structured 
interview Kiddie-SADS-PL; 2. Age range: 6-14 years. 
             Healthy control group: 1. Age range: 6-14 years. 
 
Exclusion criteria were the following:  
Children with ADHD: 1. Mental retardation (global IQ< 70 on the Wechsler 
Intelligence Scale for Children Fourth Edition plus impairment in adaptive function); 2. 
Other co-morbid psychiatric disorders; 3. Neurological diseases; 4. Current or past iron 
supplementation; 5. Current psychotropic treatment; 6. Anemia (according to age-related 
cut-offs suggested by Yip et al. 288); 7. Chronic diseases impairing iron absorption. 
 
 
Children with psychopathologies other than ADHD: 1. ADHD according to DSM-IV 
DSM-IV-TR criteria and the semi-structured interview Kiddie-SADS-PL;  2. Mental 
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retardation; 3. Neurological diseases; 4. Current or past iron supplementation; 5. Current 
psychotropic treatment; 6. Anemia7. Chronic diseases impairing iron absorption. 
 
Healthy control group: 1. Any psychiatric disorder according to DSM-IV DSM-IV-
TR criteria and the semi-structured interview Kiddie-SADS-PL; 2. Mental retardation; 3. 
Neurological diseases; 4. Iron supplementation; 5. Current psychotropic treatment; 6. 
Anemia ; 7. Chronic diseases impairing iron absorption. 
 
 
All the subjects and their parents provided written informed consent for the participation in the 
study. 
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2.3.2 Assessment and measures 
Plan of the study visits: 
V0: Screening visit 
V1: Clinical psychiatric interview   
V2: Collection of blood for the assessment of peripheral measures of iron status and MRI 
examination. 
Subjects and their parents were interviewed by the doctoral candidate during a screening 
visit to assess inclusion and exclusion criteria. An accurate developmental history (conception, 
pregnancy, delivery, birth weight, neonatal status, fine and gross motor development, cognitive and 
school functioning, toilet training and any lapses, eating behavior and attitudes, and sleep patterns), 
medical history (prenatal and perinatal complications, illnesses, medication, hospitalizations, 
serious injuries, operations) and familial history were obtained. After the clinical interview, a 
clinical psychologist administered the Wechsler Intelligence Scale for Children Fourth Edition to 
estimate the intellectual quotient (IQ). It is currently one of the most widely used intelligence scales 
for children. It is made up of 4 parts: Verbal Comprehension, Perceptual Reasoning, Working 
Memory, and Processing Speed. The full scale score is a composite of the 4 areas. 
If the subjects meet inclusion criteria and did not present exclusion criteria, they were  
invited to take part to V1 and V2. 
During V1, the diagnosis of ADHD or other psychiatric disorders was assessed according to 
DSM-IV criteria and confirmed by the semi-structured interview Kiddie- SADS lifetime version 
(Kiddie-SADS-PL)289. The Kiddie-SADS-PL is a semi-structured diagnostic interview designed to 
assess current and past episodes of psychopathology in children and adolescents according to DSM-
III-R and DSM-IV criteria. It is administered by interviewing the parent(s), the child, and finally 
achieving summary ratings which include all sources of information (parent, child, school, chart, 
and other). Questions relatives to the following diagnoses were used: Major Depression, 
Dysthymia, Mania, Hypomania, Cyclothymia, Bipolar Disorders, Panic Disorder, Agoraphobia, 
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Separation Anxiety Disorder, Avoidant Disorder of Childhood and Adolescence, Simple Phobia, 
Social Phobia, Overanxious Disorder, Generalized Anxiety, Obsessive Compulsive Disorder, 
Attention Deficit Hyperactivity Disorder, Conduct Disorder, Oppositional Defiant Disorder, 
Transient Tic Disorder, Tourette’ s Disorder, Chronic Motor or Vocal Tic Disorder, Alcohol Abuse, 
Substance Abuse, Schizophrenia. The French version of the Kiddie SADS was used in this study290.  
Data on child’s behavior were obtained by the school to corroborate the diagnosis of ADHD, 
previous consent of the parents, by means of the Revised Conners Teacher Rating Scale34 (French 
Version). 
During the first part of the V2, in the morning, blood samples were collected from each 
subject to obtain a complete blood count, and measurement of serum ferritin levels, as well as of 
serum iron and hemoglobin. Serum ferritin and iron levels were determined with commercial kits: 
ferritin levels by the Tinaquant method and iron levels by the Ferrozine method (Roche, Basel, 
Switzerland).  
After the collection of the blood samples, MRI examination was performed. As discussed in 
detail in the first part of the thesis, several relaxometry metrics have been proposed to estimate 
brain iron and, at present time, there is a lack of consensus on the most reliable MRI method to 
accurately estimate brain iron content. We chose to estimate brain iron by means of T2* because it 
has been reported as a reliable measure not only of iron overload but also of iron deficiency264. We 
used the same sequence reported in a recent paper by a group of French colleagues291 who gave us 
advice on the selection of the sequence.   
Brain MRI examination was performed on the base of the transverse relaxation rates (R2*) 
or its inverse, T2*. Changes in R2* (or T2*) reflect variations in local iron concentration. R2* are 
directly correlated with iron stores. MRI examinations were performed on a 1.5 T Philips Unit. 
Deep gray structures were localized by using a T2*-weighted echoplanar sequence. For each 
selected section, iron monitoring was performed using a single-slice multigradient echo sequence 
(field of view 28 cm, 160/160 matrix; slice thickness: 4 mm; TR: 618 ms, 17 echoes at TE from 0 
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ms to 80 ms; flip angle: 50°; acquisition time: 4 min). The determination of T2* was performed 
from data of the multigradient echo sequences using the equation: Si= So.exp (-R2*xTEi).  
Fig. 23 shows a cartography of T2* (section at caudatum level) in a patient of the research protocol. 
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2.3.3 Statistical analysis 
Sample size and power analysis: based on data provided by Allen et al.277, we calculated that 
the inclusion of about 10 patients in each of the three groups (children with ADHD, children with 
other psychopathologies, and healthy controls) would have allowed a detection of a difference of 2 
points in T2* with a power of about 85%. 
Since we planned to compare children with ADHD vs. children with other 
psychopathologies and children with ADHD vs. healthy controls, as well as children with ADHD 
vs. children with other psychopathologies plus healthy controls, we planned to include about 20 
children with ADHD, 10 children with other psychopathologies, and 10 healthy controls. 
One way analysis of variance (ANOVA) with post-hoc Bonferroni analysis for multiple 
comparisons was used to compare age, serum ferritin levels, and T2* values in the regions of 
interest among the three study groups. The correlation between serum ferritin levels was assessed 
using Spearman correlation.  
All statistical analyses were performed using the SPSS v. 15.0 software for Windows 
package for personal computers (SPSS, Inc., Chicago, IL, USA). 
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2.4 Results 
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2.5 Discussion 
--DISCUSSION OF THE RESULTS OF THIS STUDY IS CURRENTLY SUBMITTED TO A 
PEER REVIEW JOURNAL-- 
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2.6 Conclusions and future perspectives   
In spite of the above mentioned limitations, we believe that our study provides a significant 
contribution to our understanding of the pathophysiology of ADHD, suggesting that brain iron 
deficiency might contribute to the pathophysiology of ADHD via its impact on thalamic 
functioning, which is part of neuronal circuits subserving attention and alertness.     
Our study also confirms the relevance of MRI assessment of brain iron to gain insight into 
the relationship between iron deficiency and ADHD. In fact, previous studies on iron deficiency in 
ADHD have relied only on the measure of serum ferritin levels, which, according to our results, 
may be a proxy of brain iron levels but can not estimate them accurately. 
Further larger studies are necessary to replicate our results.  
Moreover, since we used T2* values to estimate brain iron and this metric presents some 
limitations (these values may be hampered by local background sources of magnetic field 
variation)232, further studies should assess brain iron levels by means of novel approaches 
(including susceptibility-weighted imaging, magnitude imaging, and phase imaging231) which may 
estimate brain iron in a more accurate way. 
Furthermore, it would be interesting to compare estimated brain iron levels in different types 
of ADHD (“predominantly inattentive”, “predominantly hyperactive-impulsive”, “combined”) and 
to assess the correlation between estimated brain iron levels and severity of ADHD. 
Finally, since it has been reported that children with ADHD present with higher activity 
levels than controls not only during daytime but also in sleep292, and since we293 have recently 
reported that low serum iron levels correlate with high nighttime activity in ADHD, it would be 
noteworthy to assess the correlation between nighttime activity and estimated brain iron levels. 
All this body of research might contribute to advance our knowledge on the 
pathophysiologic pathways underlying the cluster of ADHD symptoms. The approach which 
underlies the rationale of these studies is an innovative one in the field of ADHD, and, in general, in 
child psychiatry, moving from the description of syndromes to pathophysiology-based disorders. 
 135 
This approach would also lay the groundwork for interesting treatment applications. In fact, ADHD 
medications act on the dopaminergic and noradrenergic system. Interestingly, it has been reported 
that the effect of drugs acting on the dopaminergic and noradrenergic systems is reduced in the 
presence of iron deficiency159. Therefore, if further research confirms low brain iron levels in 
ADHD, it would provide a strong rationale for trials assessing the effects of ADHD medications 
plus iron supplementation for daytime ADHD symptoms and associated nighttime hyperactivity. 
This might contribute to improve current clinical practice, allowing for a better quality of 
life for children with ADHD and their families. Therefore, given the tremendous social and personal 
impairment associated with ADHD, further research on the relationship between iron deficiency 
and ADHD is worthwhile.  
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